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ABSTRACT
SELECTIVE LESION OF CHOLINERGIC NEURONS OF THE SEPTAL
HIPPOCAMPAL TRACT: MEMORY AND LEARNING

By
Nicholas Fitz
May 2009

Dissertation supervised by David A. Johnson Ph.D.
It is hypothesized that the loss of cholinergic function in the medial septum (MS),
observed early in many forms of dementia, contributes to memory losses characterized in
these diseases. The studies of this dissertation examined whether the selective loss of
cholinergic neurons in the MS impairs acquisition of a delayed matching-to-position
(DMP) spatial memory task.

The results suggest a significant contribution of MS

cholinergic neurons in acquisition of the DMP task. Specifically, 192 IgG-saporin SAP
lesioned rats acquired the task at a slower rate and required more days to reach criterion.
The results also suggest that male rats typically adopt a consistent turning strategy early
in the training process, which is independent of extra-maze cues. For animals to reach
criterion, an alternative learning strategy was adopted; one dependent on extra-maze
cues. Cholinergic lesion of the MS resulted in a greater reliance on a consistent turning
strategy, which accounted for the slower rate of acquisition of the DMP task.
iv

Steroid sulfatase inhibitors increase whole brain DHEAS levels, enhance ACh
release in the hippocampus, and enhance memory. The present study also investigated
the cognitive effects of sulfatase inhibition in SAP lesioned animals. Steroid sulfatase
inhibition further impaired acquisition of the DMP task in SAP lesioned rats while having
no effect on cholinergically intact animals. Since DHEAS displayed memory enhancing
properties in rodents, we also investigated the effects of DHEAS administration on MS
SAP lesioned animals. DHEAS treatment had no significant effect on the acquisition of
the DMP task in the SAP treated or control animals.
The final study of this dissertation examined the effect of arousal on DMP
performance in SAP lesion of the medial septum. Arousal, induced by the IP injection of
saline, decreased the number of days SAP lesioned rats needed to reach criterion and also
improved the rate of acquisition. The results suggest that a mild aversive stimulus can
attenuate cognitive deficits caused by MS cholinergic lesions.

v
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I. INTRODUCTION
A. Literature Review
1. Dementia:
Dementia is a syndrome characterized by neuropsychological, neuropsychiatric,
and neurologic manifestations. Particularly affected functions include memory, attention,
language, and problem solving. Symptoms of dementia can be reversible or irreversible.
Reversible causes of dementia include hypothyroidism, Vitamin A, B1, or B12 deficiency,
tumors, normal pressure hydrocephalus, or syphilis; but these only account for less than
10% of clinical cases. Irreversible dementias include Alzheimer’s disease, vascular
dementia, alcohol induced persisting dementia, and frontotemporal lobar degeneration.
There is an estimated 24 million people worldwide with clinical symptoms of dementia,
and this number is projected to increase to 81 million by 2040 (1).
Alzheimer’s disease (AD) is the most common type of dementia in the elderly,
affecting almost half of all patients with dementia. More that 5 million Americans are
estimated to have AD and it is projected that 14.3 million Americans will develop the
disease by 2050; a 350% increase from 2000 (2). Among patients 65 years of age, 2-3%
display symptoms of the disease, while nearly 50% of patients 85 years of age or older
have symptoms of AD and an even greater number display some of the pathological
hallmarks of the disease without presenting the symptoms. Statistics show that for every
five years a person lives past the age of 65, the probability of developing the disease
doubles (3). As global life expectancy rises, patients over the age of 85 are the fastest
growing segment of the AD population. Therefore, advanced aging is a primary risk
factor for the disease. Clinicians who diagnose and treat patients with AD generally
1

recognize that the prevalence of AD is higher in women (3). Possibly due to the relative
lack of a protective factor, such as the estrogen deficiency of postmenopausal women,
which may increase the vulnerability to AD pathology.
For most patients diagnosed with the disease, increased impairments in learning
and short-term memory will lead to a diagnosis of dementia, while small populations may
also display signs of language and visual-spatial difficulties (4). Memory problems do
not affect all memory capacities equally, with older memories of the patient’s life, facts
learned, and implicit memory commonly spared (5-6). These initial symptoms progress
from simple forgetfulness and the inability to navigate simple tasks, to more persistent
losses of short-term memory and difficulty navigating through familiar areas, such as
one’s own home. As the disease progresses to the moderate stage of memory loss,
patients fail to recognize familiar objects and persons (4). During this stage of the
disease, patients may also show changes in behavior, such as violent outbursts or
excessive passivity without prior history of such behaviors. In late stages of the disease,
patients lose the ability to perform even simple tasks independently. Patients become
incontinent of bladder and bowel, and/or lose the ability to walk or eat without assistance.
In late stages of AD, language becomes disorganized and then lost altogether.
Eventually, the ability to swallow food or drink is lost, ultimately leading to death (4). In
2004, with 65,829 deaths, AD was the seventh leading cause of death in the United States
(7). The mean duration of the disease is 8.5 years between onset of the clinical symptoms
and death. At a cost of over $100 billion per year, AD is the third most costly disease in
the United States, after heart disease and cancer. Direct and indirect costs for long term
care for an Alzheimer’s patient averages $77,500 per year (8).
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Regions associated with higher brain function, particularly the neocortex and
hippocampus, are most affected by the pathology of AD. Pathological changes include
extracellular deposits of β-amyloid, a proteolytic byproduct of the transmembrane protein
amyloid precursor protein. Although β-amyloid monomers are soluble and harmless,
they undergo a conformational change at high concentrations to form a β-sheet rich
tertiary structure that aggregates to form amyloid fibrils. These amyloid fibrils are
deposited extracellularly, forming dense senile plaques.

Another pathological

characteristic of AD is abnormal aggregation of tau protein, a microtubule associated
protein expressed in neurons that normally acts to stabilize microtubules in the
cytoskeleton. Like most microtubule-associated proteins, tau is normally regulated by
phosphorylation.

However in AD patients, hyperphosphorylated tau accumulates as

paired helical filaments that form intracellular neurofibrillary tangles and dystrophic
neurons associated with amyloid plaques (9). There is also a significant loss of neuronal
synapses and pyramidal neurons within the brain regions associated with higher cognitive
function. The cholinergic basal forebrain neurons are one of the most sensitive targets of
degenerative processes occurring in patients with AD (10-11).
Three major competing hypotheses exist to explain the cause of Alzheimer’s
disease. The cholinergic hypothesis of AD proposes that degeneration of cholinergic
neurons in the basal forebrain and the associated loss of cholinergic neurotransmission in
the cerebral cortex and hippocampus contributes significantly to the deterioration of
cognitive function seen in AD patients (12). In support of this hypothesis, postmortem
AD brains are characterized by neuronal loss and neurofibrillary tangle formation in
regions of the neocortex and hippocampus, primarily affecting pyramidal neurons and

3

their synapses (13-14). Furthermore, neurotransmitter specific projections to the cortex
and hippocampus are affected by neurodegenerative processes, including cholinergic
nucleus basalis and medial septum projections (11). For example, AD affected brains
have an almost 80% reduction in cholinergic neurons of the nucleus basalis compared to
age-matched control brains. Biochemical examination of biopsy tissues from patients
with AD 3.5 years following the onset of symptoms indicate selective cholinergic
pathologies occur early in the course of the disease (15).

Specifically, presynaptic

markers of cholinergic activity are greatly reduced.

Reduction of choline

acetyltransferase (ChAT) activity and acetylcholine (ACh) synthesis were strongly
correlated with the degree of cognitive impairment in AD patients (15-18). Subsequent
findings of reduced choline high-affinity uptake, impaired ACh release, deficits in
expression of nicotinic and muscaric cholinergic receptors, and loss of cholinergic soma
from the nucleus basalis confirmed a substantial presynaptic deficit (reviewed in 19).
Cholinergic effects have also been proposed to initiate large-scale β-amyloid aggregation
leading to generalized inflammation (20).

In further support of the cholinergic

hypothesis for AD, anticholinergic drugs impair learning and memory in a way that was
similar to that observed with AD (21). Currently, despite these findings, the cholinergic
hypothesis is not widely accepted. Even if the disruption of the cholinergic system is not
the first stage of the pathogenesis of AD, it is still a major event that is involved in the
loss of cognitive function, a key hallmark of the disease.
The other hypotheses for the pathogenesis of AD focus on the effects of the
misfolded and aggregated proteins β-amyloid and tau. One hypothesis states that tau
hyperphosphorylation initiates the disease cascade, while another hypothesis states that β-
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amyloid deposits are the initiating factor.

The tau hypothesis is supported by the

observation that the deposition of amyloid plaques do not correlate well with the neuronal
loss observed in AD (22).

The cloning of the gene encoding the β-amyloid precursor

protein and its localization to chromosome 21, coupled with the earlier observation that
Down’s syndrome (Trisomy 21) mimics the neuropathology of AD, lead to the
hypothesis that β-amyloid accumulation is the primary event in AD pathogenesis. The
formulation of the amyloid hypothesis points to the cytotoxicity of mature aggregated
amyloid fibrils, which are thought to disrupt calcium homeostasis and thus induce
apoptosis (23-24).
There is currently no cure for AD and the medications currently available offer
only small symptomatic benefit for some patients, but do not slow disease progression.
Approaches for treating AD disease have focused on augmenting cholinergic function,
since decreased central cholinergic activity appears to be an important component of the
pathology of memory and attentional deficits associated with AD. Drug therapies can
enhance

cholinergic

function

through

several

different

mechanisms.

Acetylcholinesterase (AChE) inhibitors (tacrine, donepezil, galantamine, rivastigmine)
enhance cholinergic function by inhibiting the hydrolysis of ACh and therefore, heighten
the concentration of ACh at the post-synaptic receptor sites.

Unfortunately, AChE

inhibitors, aside from being marginally effective, are also limited by a lack of specificity.
Moreover, they do not alter the course of the underlying disease process.

5

2. Learning and Memory
Learning is the cognitive process of acquiring skills, knowledge, and
understanding from study, instruction, or experience that help guide long term behaviors.
During animal behavioral testing, learning occurs when a new response becomes
associated with a particular stimulus is termed associative learning. Associative learning
occurs through classical and instrumental conditioning.

The typical procedure for

inducing classical conditioning involves presentation of light or sound followed by
administration of food. During classical conditioning animals learn to associate the light
with food. Habituation is the waning of an animal’s behavioral response to a stimulus.
Habituation is usually considered a form of learning which involves the elimination of
behaviors that are not needed by the animal. Habituation is separated from most other
forms of decreased response on the basis that the change in behavior is permanent;
habituated animals do not resume earlier reaction to the stimulus after a period of nonstimulus. Learning would be extremely inefficient if humans had to rely completely on
classical and instrumental conditioning.

Unlike in animals, humans can acquire

information through cognitive learning. Cognitive learning is defined as the acquisition
of knowledge and skill by mental processes, observation, instruction, and imitation of
behavior. In cognitive learning, the individual learns by listening, watching, touching,
reading, or experiencing.
Memory is defined as the mental faculty of retaining and recalling past
experiences (25). From an informational processing standpoint there are three stages in
memory formation: encoding, storage, and retrieval.

Encoding is the processing of

sensory input into memory. During memory encoding, information is processed about
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space, time, and frequency. Storage is the organization of the encoded information that is
retained in sensory, short-term, or long-term memory. Retrieval of memory involves the
recall of stored information and can be classified into three different categories: free
recall (no clues given to assist retrieval), serial recall (items recalled in a particular order),
and cued recall (clues given to assist retrieval) (26). During retrieval of memories
neurons are activated and fired in the same pattern as during the encoding process.
Memory can be generically classified on the bases of the duration of memory
retention (26).

In this classification system memory can be divided into: sensory

memory, short-term memory, and long-term memory. Sensory memory is the retention
of impressions of sensory information after the original stimulus has ceased. It refers to
items detected by sensory receptors which are retained temporarily in the sensory
inventory. Sensory inventory has a large capacity for unprocessed information but is
only able to hold accurate images of sensory information momentarily.

Without

rehearsal, sensory memory typically lasts less than 1 sec and no more than 2 sec. Visual
sensory memory is commonly called iconic memory, while auditory sensory memory is
referred to as echoic memory.

Typically tests of iconic memory involve exposing

subjects to a grid of three rows of four letters for a brief period. Participants must then
recall as many letters as they can and also the row in which the letters were found.
Short-term memory is defined as the capacity to hold a small amount of
information in an active, readily available state. Short-term memory can hold a small
amount of information from a few seconds to a minute without rehearsal. Like sensory
memory, short-term memory has a limited capacity, estimated at 3 to 9 elements. Items
held in short-term memory include: recently processed sensory input, recently retrieved
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long-term memories, and the results of recent mental processing. A special form of
short-term memory, working memory, refers to the temporary storage and manipulation
of information needed for language comprehension, learning, and reasoning (27).
Working memory is unique in that it requires the simultaneous storage and processing of
information. Working memory can be generally divided into three subcomponents: 1.
central executive, an attentional-controlling system important for problem solving tasks;
2. visuospatial sketchpad, manipulates visual images; and 3. phonological loop, stores
and rehearses speech-based information.
Long-term memory can store information for as little as a few days or as long as
decades. Unlike sensory and short-term memories, long-term memory has an unlimited
capacity. Short-term memory is supported by a temporary potentiation of neuronal
connections, especially in the frontal and parietal lobes. Specific patterns of neuronal
connections distinguish different memories. A stronger neuronal connection encoding a
stimulus will result in a stronger associated memory. Through rehearsal and association
this temporary potentiation can be processed into long-term memory. The proposed
mechanism by which short-term memories move to long-term memory is via long-term
potentiation (LTP), which results in physical changes in the structure of neurons. Longterm potentiation is the long lasting enhancement in communication between two neurons
simultaneously stimulated (28, 29).

LTP shares several properties with long-term

memory, making it a candidate for the cellular mechanism of learning. Both LTP and
long-term memory are rapidly induced, stimulus specific, rely on the formation of new
proteins, and last for months following exposure to the original stimulus (30). It is
widely accepted that during long-term memory formation changes in protein synthesis
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controls synaptic strength via rapid protein production from preexisting mRNA. Protein
synthesis is required for several forms of synaptic plasticity (31-34). Synaptic plasticity
is a physiological phenomenon whereby specific patterns of neural activity give rise to
changes in synaptic efficacy and neural excitability that outlast the initial stimulus (35).
It is thought that changes in synaptic patterns underlie the storage and recall of memory.
Various neurotransmitters in the brain, including acetylcholine, γ-aminobutyric acid
(GABA), adrenergic and glutamertergic systems have been shown to play a significant
role in memory function (33-37).
Memory formation and storage involves complex communications between
different cortical and subcortical structures of the brain, with no single site of memory
formation and storage (38). The cerebellum, the limbic system (hippocampus, amygdala
and the thalamus) and the cortical areas of the brain have been associated with memory
storage and retrieval (39). Each structure has been associated with the encoding and
retrieval of different memory types. Clinical case in humans (40-43) and animal studies
of hippocampal lesions (43-46) demonstrate the importance of the hippocampus in
memory acquisition. Specifically, it is thought that the hippocampus is important in
short-term storage of sensory stimuli. Following the initial stimulus, the hippocampus
coordinates the spontaneous retrieval of different components of an experience and relays
these unique components to different memory systems depending on the memory type
(47). Declarative memory is an aspect of human memory pertaining to the storage of
facts, dates, and life events. This type of information is relayed to perirhinal cortex and
medial temporal lobe (48-50). Memories of skills, procedural memory, is relayed to the
striatum, neocortex, or to the cerebellum depending on the aspect of the skill. The
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cerebellum is involved in the storage of reflexes while the striatum and neocortex stores
information about the skills.
Two memory types studied during cognitive testing in rodents include working
memory and reference memory. Working memory is defined as short term memory for
an object, stimulus, or spatial location that is used within a testing session, but not
typically between sessions. This is distinguishable from a form of long-term memory
termed reference memory, which is a memory that is typically acquired with repeated
training, and would persist for days to months. Reference memory is often the memory
for the rules of a particular memory paradigm; for example, that an operant lever press
produces a reward, or that a hidden platform is found in the Morris water maze. Working
memory is typically a delay-dependent representation of stimuli that is used to guide
behavior within the task. Working memory functions on a particular trial of a task, but
then must be forgotten or ignored on subsequent trials (27).
Two major learning paradigms are commonly used in rodent studies of cognition.
Conditional learning paradigms are used due to the ease of controlling the conditioned
stimulus. Spatial learning tasks are among the most commonly used tests for detecting
potential cognitive enhancers and cognitive changes associated with aging.
Conditioned learning tasks can involve aversive or reinforcement stimuli.
Avoidance tasks measure memory of an aversive event, through simple avoidance of the
location in which the aversive stimulus was first experienced.

The animals avoid a

location, (for example a dark room) where they previously received an aversive stimulus
(foot shock). An avoidance task can require either a passive or active response. With a
passive avoidance task an animal is placed in a lighted room; having a natural disposition
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for the dark the rodent will leave the lighted room and enter the darkened room. Once it
enters the dark room a foot shock is administered, providing a stimulus which helps the
animal learn on subsequent trials to stay in the lighted room. When the aversive stimulus
is made predictable the animal can then actively avoid the stimulus. In an avoidance
paradigm, task performance is measured by the ability of the animal to avoid the
compartment where a shock has occurred during the training phase of the paradigm. In
reinforcement paradigms, animals can learn an operant lever press to gain access to an
appetitive stimulus such as water or food.
In spatial learning tasks, the animal’s behavior can be driven either by an aversive
stimulus where the goal is to find refuge (finding a platform in the Morris water maze
task), by an appetitive stimulus (water or food), or by spontaneous choice exploration
(novel arm versus familiar arm). The Morris water maze requires rats to find the location
of a submerged invisible platform in a large circular pool of water. One version of the
task that tests reference memory is typically run by submerging the platform in the same
location in the pool across days.

The rat solves the task by learning the spatial

relationships between the platform location and extramaze landmarks in the testing
environment. Evidence of the rat learning the location of the hidden platform is observed
with a shorter time latency to swim to the platform during subsequent trials. Working
memory versions of this task have also been developed, with the location of the platform
changed each day of testing. Working memory versions of the water maze require the
animal to remember the location of the hidden platform during multiple trials in a training
day, but forget this location on the next day of training. Again, evidence of the rat
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learning the location of the hidden platform is seen with shorter latency to swim to the
platform as the number of trials increase for that training day.
A classical task for testing memory in rodents is the radial arm maze. The maze
is comprised of a center platform with radiating arms (6-12 arms). In this task, the rat is
placed in the center platform, and a food reward is available at the ends of each of the
arms. Working memory is tested by determining the number of arms entered before all
of the food reward is recovered. It is observed that rats retrieve the food from each arm,
and quickly learn to visit all the arms without re-entering a previously visited arm. A
version of the radial arm maze has also been developed to test working and reference
memory at the same time. In this version of the task, a predetermined number of arms
are baited. The same maze arms are baited each day, across sessions, the rats must learn
to ignore the unbaited arms. Entry into an unbaited arm is considered a reference
memory error, while within a session re-entering a baited arm is considered a working
memory error.
The T-maze task can be utilized to test delayed alternation or matching to position
tasks. Delayed alternation tasks rely on the rats’ tendency to choose alternative maze
arms or locations when rats are re-exposed to the apparatus. The task works as follows:
a rat is placed into the base (start location) of the T. The rodent runs up the stem of the
maze and enters one arm of the T, where it then obtains a reward. The rat is picked up by
the observer and returned to the base of the T. Typically the rat will run up the stem and
enter the arm of the T that was not entered on the previous trial. Rats tend to alternate
without reinforcement; which is referred to as spontaneous alternation.
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A delayed matching to position task (DMP) can be used to offset the
natural tendency of spontaneous alternation. This task is performed in a similar way to
the alternation task except on the second trial the animal must enter the same arm as
previously entered in order to receive the food reward. The DMP task typically requires
more days of testing for the rodents to learn the task. The animal must remember the
initial response to repeat the response, thus this is a working memory task. Typically, it
is assumed that the rats solve the T-maze by remembering the location of the most
recently visited arm based on its spatial relationship with extramaze cues. Remembering
the spatial relationship of cues to guide behavior is considered allocentric spatial
memory. The rat, however, may solve the task utilizing their directional sense, for
example, first going east and then going west. The rat may also remember which turn it
has made (left) and make the opposite or same turn on the subsequent trial. By doing
this, the rat would adopt an egocentric strategy. Egocentric strategy, also term response
learning, involves rotating in a self centered spatial framework in response to a cue.
Guidance strategy consists of approaching or avoiding an object or cue in the
environment. The use of this type of strategy is known as “cue learning”. Finally, if
subtle odor cues are left in the maze, the rat may detect the arm that was most recently
entered by olfaction. It is unlikely that animals use only one learning strategy during
acquisition of a T-maze task. It is more likely that learning in this task requires the
adoption of multiple learning strategies during different periods of training.
Neurons in the hippocampus code spatial location (41-42), and performance
within the T-maze is particularly sensitive to the effects of hippocampal disruption (3740). Damage to the hippocampus and its connections produce significant impairments in
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many forms of the T-maze task. Therefore, it is likely that damage to the hippocampus
diminishes the ability of rodents to use spatial relationships in the environment to guide
navigational behavior.

These animals could still use either egocentric or guidance

strategies, which are mediated by non-hippocampal structures.

3. Overview of Acetylcholine as a Neurotransmitter:
Acetylcholine (ACh) is a major neurotransmitter in both the mammalian
peripheral nervous system and mammalian central nervous system (CNS) (51). Within
the peripheral nervous system, acetylcholine is involved in the coordination of skeletal
and smooth muscle contraction, control of heart rate, and regulation of endocrine gland
secretions. Within the central nervous system, acetylcholine is implicated in emotional
and attentional processes, learning, memory, and arousal (51-55).

Illustration 1: The synthetic pathway for acetylcholine.
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Acetylcholine is synthesized in a reaction catalyzed by the enzyme choline
acetyltransferase (ChAT) from acetyl coenzyme A (CoA) and choline. Acetyl CoA
primarily arises from glucose in the mitochondria through glycolysis and the pyruvate
dehydrogenase system; from citrate, either by reversal of citrate synthesis or by citrate
cleavage; or from acetate through acetate thiokinase (56,57). Following hydrolysis of
ACh, 30-50% of the liberated choline is transported back into the presynaptic neuron
through a high affinity choline transporter. The remainder of the choline is catabolized or
incorporated into phospholipids where it can be used as a future source of choline. The
uptake of choline is the rate limiting factor in the synthesis of ACh (56). Acetylcholine
esterase normally hydrolysizes acetylcholine into its inactive metabolites. This enzyme is
abundant in the synaptic cleft of neural tissue, and its role of clearing ACh from the
synaptic cleft is essential for proper functioning of the cholinergic system (2, 56, 57).
Cholinergic receptors fall into two classes, muscarinic and nicotinic. Currently
five muscarinic receptors (M1-M5) have been identified, each produced by a different
gene. All muscarinic receptor subtypes are G-protein coupled metabotropic receptors
that contain seven hydrophilic transmembrane domains, and transduce a signal that
activates a number of second messenger systems. The M1, M3, M5 receptors are coupled
via Gq to phosphatidylinositol hydrolysis and M2 and M4 receptors via Gi are coupled to
cyclic adenosine monophosphate. The cellular effects of muscarinic receptor activation
include either opening or closing of K+ channels, Ca2+ channels, or Cl- channels,
depending on the receptor and cell type.

Therefore, the stimulation of muscarinic

receptors can result in either depolarization or hyperpolarization of a neuron.
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The nicotinic ACh receptor is a pentameric integral membrane protein composed
of five different polypeptide chains (α, β, γ, δ, ε). To date 17 nicotinic ACh receptors
have been identified, which are divided into muscle-type and neuronal-type subunits.
Neuronal-type nicotinic receptors can be divided into two subtypes: 1.) the high affinity
agonist binding class, which fails to bind α-bungerotoxin and is a heteropentameric
nicotinic receptor formed by α2-α6 and β1-β4 subunits; and 2.) lower affinity binding
class that binds α-bungerotoxin and is usually homopentameric formed by α7-α9
subunits (51). Acetylcholine binds to the α subunit causing a conformational change in
the channel that selectively allows cations (Na+ and Ca+) to pass through the membrane,
leading to a rapid depolarization and excitation.

Nicotinic receptors are located at

skeletal neuromuscular junctions, autonomic ganglia, adrenal medulla and CNS (56,57).

Illustration 2: Cholinergic system of the rat brain. Notice the major cholinergic
innervation of the hippocampus by the medial septum. ms- medial septum, vdb- vertical
diagonal band of Broca, hbd- horizontal diagonal band of Broca, bas- nucleus basalis
magnocellularis, si- substantia innominate , ppt- pendunculopotine, ldt- laterodorsal
tegmental nuclei (51).
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The cholinergic system in the brain can be divided into four main components:
the basal forebrain cholinergic system, pontine (brainstem) cholinergic system, motor
neurons and cholinergic interneurons.

The basal forebrain and pontine cholinergic

systems contain projection neurons connecting two or more different regions.
Cholinergic interneurons are classified as local circuit cells, which are morphologically
arranged within one neuronal structure, and are exemplified by the interneurons of the
caudate putamen nucleus, nucleus accumbens, olfactory tubercle and islands of Calleja
complex. Motor neurons are located within the CNS and project their axons to the
periphery

where

they

directly

or

indirectly

control

muscle

movements.

Within the CNS, the motor neurons originate from the primary motor cortex, brain stem
and cranial nerve nuclei. The pontine cholinergic system contains cholinergic neurons in
the pendunculopotine and laterodorsal tegmental nuclei, which project to the thalamus,
pontine, other diencephalic loci, medullary formations and cranial nerves (58).
Acetylcholine containing neurons of the basal forebrain located in the nucleus
basalis magnocellularis (NBM), the diagonal band of Broca (DBB) and the medial
septum (MS), give rise to projection neurons innervating the cerebral cortex, the
amygdala, the hippocampus and several thalamic nuclei (59-60). The NBM contains the
primary concentration of cholinergic neurons that project to the neocortex, while the
DBB contains a cholinergic bundle of nerve fibers that interconnects the paraterminal
gyrus, in the septal area, with the hippocampus and lateral olfactory area.

The

septohippocampal tract is formed by the cholinergic projection neurons from the MS to
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the hippocampus and provides the greatest cholinergic innervation of the hippocampus
(59,60).
It was observed that hippocampal ACh release increased during performance of a
learned spatial memory task (61,62), and the improvement in radial arm maze
performance was positively correlated to the increase in ACh release during 12 days of
task learning (63).

These results demonstrated that the learning of the spatial task

modified the function of cholinergic neurons projecting to the hippocampus, which
become progressively more active.

Furthermore, spatial discrimination learning

selectively increased muscarinic ACh receptor immunoreactivity in CA1-CA2 regions of
the hippocampus, and in the neocortex, but not in the amygdala (64).
Memory processes are mediated by independent and/or competing parallel
neuronal systems (for a review see 65). It has been demonstrated that hippocampal ACh
release increases both when rats are tested in a hippocampal dependent spontaneous
alternation task and an amygdala dependent conditioned place preference (CPP) task
(66).

The magnitude of hippocampal ACh release was negatively correlated with

performance in the CPP task, indicating not only a competition between the two
structures, but also that activation of the cholinergic hippocampal system inhibited the
expression of amygdala dependent memory. However, competition was not the only
interaction between the hippocampus and the amygdala, because it has been reported that
ACh release in the amygdala was positively correlated with performance in a
hippocampal spatial working memory task (66). The two structures seemed to have a
nonreciprocal interaction in that the hippocampus competes with the amygdala, but the
amygdala cooperates with the hippocampus during learning.
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In the plus maze task, the time course of ACh release in the hippocampus and the
striatum differed during training. The hippocampal cholinergic system was activated first
during training and was involved in a place strategy depending on spatial memory; the
striatal cholinergic system was activated later in training, when the rats shifted to
response strategy to solve the maze (67). Studies indicated that the cholinergic projection
neurons may not only be important for learning but may also be important for attentional
processes (68). Microdialysis experiments indicated that cortical ACh increase during
performance of a simple operant task was limited to early acquisition stages, when the
attentional demand is high (69). Similarly, large increases in cortical and hippocampal
ACh release were observed during acquisition of a reward operant task, but not during
recall of the task (70). Intraparenchymal injections of a selective neurotoxin disrupted
attentional processing in NBM- and MS-infused animals, thus confirming the role of the
cholinergic system in attention (71).

4. Central Cholinergic Immunolesioning with SAP:
The cholinergic hypothesis of AD proposes that degeneration of cholinergic
neurons in the basal forebrain and the associated loss of cholinergic neurotransmission in
the cerebral cortex and hippocampus contribute significantly to the deterioration of
cognitive function in AD patients (72). To study the contributions of cholinergic basal
forebrain neurons to the establishment of the cognitive features of AD, animal models are
required that specifically mimic cholinergic cell loss in the basal forebrain and cortical
cholinergic hypoactivity.

Classical methods that relied on fimbrial transactions,

mechanical lesions, chemical injections of quisqualic acid, α-amino-3hydroxy-5-methyl-
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isoxazole-4-proprionic acid (AMPA) and ibotenic acid failed to induce complete and
selective cholinergic cell death in the basal forebrain (72-74). The main reason for this
complication was that cholinergic neurons of the basal forebrain are intermingled with
GABAergic and other neurons, which have similar projection targets that also influence
memory function. Therefore, nonselective lesions confound the interpretation of the
behavioral results from these animal models.
An understanding of the role of basal forebrain in learning and memory has
accelerated since the development of immunotoxins such as 192-IgG-saporin (SAP).
SAP provides a more efficient and selective tool to induce permanent cortical
hypofunction. The immunotoxin was constructed through a disulfide bond linkage of the
monoclonal antibody 192IgG and the plant alkaloid saporin (75).

192IgG is a

monoclonal antibody raised against the low affinity nerve growth factor receptor (p75
NGF receptor), while saporin, obtained from Saponaria officinalis, is a potent ribosomeinactivator (76). p75 NGF receptors are extensively expressed on the soma and terminals
of the cholinergic neurons of the basal forebrain (77). This neurotoxic complex binds to
the p75 NGF receptor found on cholinergic neurons of the basal forebrain. Like the
endogenous ligands for the p75 NGF receptor, the toxin is internalized after binding, and
is reterogradely transported back to the soma (78). The saporin toxin is cleaved from the
antibody and escapes the endosome, allowing saporin to enzymatically inactivate the
large ribosomal subunit of the protein complex. Inactivation of this complex inhibits
protein synthesis, ultimately leading to neuronal death (76).
Following ventricular injections, the immunotoxin is taken up by cholinergic
neurons of the basal forebrain resulting in cholinergic losses in the MS, DBB, and NBM;
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whereas, adjacent cholinergic neurons in the ventral pallidum and caudate putamen are
spared (79). The MS and DBB contain cholinergic and GABAergic neurons which both
project to the hippocampus. Ventricular injections had no effects on the GABAergic
neurons of the basal forebrain, but affected purkinje fibers which also express p75 NGF
receptors (79).

The latter needs to be considered during behavioral testing since

destruction of the purkinje fibers have been associated with severe motor deficits in rats.
Histological experiments demonstrated that localized infusion of SAP into the
three distinct loci of the basal forebrain resulted in a complete loss of NGF
immunoreactive neurons within the areas of interest (80). Following localized infusions
of SAP, sections stained for a cholinergic marker, AChE, also showed a loss of
cholinergic neurons in distinct loci. A dramatic reduction of AChE staining in the target
areas (dorsolateral neocortex, cingulated cortex and hippocampus) was associated with
the distinct region of the basal forebrain which provides cholinergic innervation.
Similarly ChAT activity in the targeted areas displayed reduced activity, further
demonstrating cholinergic hypoactivity (81). Localized infusion of SAP did not affect
cholinergic neurons which lacked p75 NGF receptor expression. Localized infusions of
higher SAP doses (1 μg) directly into the basal forebrain induced lesions of all
cholinergic neurons within the basal forebrain and other non-cholinergic neurons
expressing p75 NGF receptors including the purkinje fibers (82). Smaller doses of SAP
(0.22 μg) injected directly into selected loci of the basal forebrain, like the MS, spared
not only the purkinje fibers but also GABAergic neurons present in the MS (82). Effects
on GABAergic neurons should be considered because of the important role they play in
regulating hippocampal function. The intensity of staining for parvalbumin, a calcium
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binding protein expressed by a subset of GABAergic neurons in the MS, is examined to
detect changes in the population of GABAergic neurons present in the MS. At the 0.22
μg dose of SAP, there is no effect observed in the intensity of parvalbumin staining,
compared to the decreased staining with higher doses of SAP (82). Thus, injections of
low doses of SAP directly into individual basal forebrain loci could provide an excellent
tool for dissociating the role of cholinergic basal forebrain nuclei and their projections in
mediating cognitive processes.

5. Role of Dehydroepiandrosterone and Dehydroepiandrosterone Sulfatase in
Cognition:

Illustration 2: Structural relationship between dehydroepiandrosterone and its sulfated
form

Dehydroepiandrosterone (DHEA) and its sulfated ester dehydroepiandrosterone
sulfate (DHEAS) have gained significant interest in the field of neuroscience due to two
findings: a strong age associated decline of the steroid in humans and the demonstration
of DHEA(S) metabolism and action in the rodent brain. DHEAS is the most abundant
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steroid product of the adult human adrenal cortex with concentrations in the microgram
per milliliter range (83). In addition to its adrenal origins, DHEA is also produced in
small amounts (10-20% of circulating hormone) within the gonads and CNS (84,85).
Formation of DHEA is stimulated by adrenocorticotropic hormone from the pituitary, has
a short serum half-life (30 min. or less), and a serum concentrations that fluctuate
markedly with the circadian rhythm. DHEAS has serum concentrations greater than 200
times that of DHEA and has a much longer half-life (7-10 hours), which largely removes
the variation in plasma concentration associated with circadian rhythm (86-90). Due to
the short half life (30 min) and quick catabolism of DHEA, less than 1% of the steroid is
in circulation as the unsulfated form (91). Most of the DHEAS (60-80%) entering the
blood is converted to DHEA by steroid sulfatase, while a small amount of DHEA (5-7%)
is converted to DHEAS by hydroxysteroid sulfotransferase in the liver, kidney, and CNS,
creating an equilibrium between the two isoforms (89, 92). DHEA(S) exhibits a strong
and unique developmental pattern.

Illustration 3: Unique developmental pattern for DHEAS
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DHEA is produced in the fetal adrenal glands, with concentrations sharply
dropping and becoming almost undetectable 6 months following birth (93). One to two
years after puberty a rise in DHEA production occurs, with a peak concentration obtained
during the third decade of life (83, 94-95). Thereafter, a marked continuous decline in
DHEA(S) concentration is observed with patients in their sixth decade of life, possessing
only 20% of plasma concentrations compared to pubescent patients. This developmental
pattern is observed in both males and females, with males having higher DHEAS levels
in adulthood (96-99). This strong age-associated pattern is not observed for cortisol, the
primary human glucocorticoid secreted from the adrenal cortex, where basal levels are
unchanged or slowly increase throughout the life-span (100, 101).
Neuroactive steroids are endogenous compounds with neuromodulatory effects
(102). Several of these compounds, such as estrogens and corticosterone, have been
shown to enhance cognitive function in rodents and have gained significant interest as
potential therapeutic regiments for dementia and age-associated memory loss (for a
review see 103). In the rodent brain, estrogen supplementation has been shown to
enhance ChAT activity, high affinity choline uptake, and the release of ACh in the
hippocampus following potassium stimulation (104-106).

Moreover, studies have

demonstrated that estrogen supplementation can reduce the incidence and severity of
Alzheimer’s disease in post menopausal women (107).
A subset of neuroactive steroids, termed neurosteroids, accumulates in the
nervous system independent of the products of steroidogenic endocrine glands.
Neurosteroids are synthesized de novo in the nervous system from sterol precursors.
Neurosteroids have also been shown to modulate neuronal activity within the central
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nervous system (102).

There is substantial evidence that DHEA and DHEAS are

produced within the CNS and are therefore neurosteroids (102).

DHEA(S)

concentrations in the rodent brain far exceed peripheral concentrations and are
independent of adrenal synthesis (108, 109). However, the exact metabolic pathway(s)
for DHEA(S) in the rodent brain are still not completely understood, since P 450-17α (17
α hydroxylase; the enzyme which converts pregnenolone into DHEA) is present in the
fetal, but not in the adult rodent brain (110). Furthermore, within the rodent brain there is
a small amount of hydroxysteroid sulfotransferase activity. These findings suggest that
DHEA, which passes the blood brain barrier more readily than DHEAS, could be locally
converted to DHEAS in the brain (111, 112). Sulfatase activity is widely present in the
CNS and its pharmacological inhibition affects memory (113-117).

Others have

suggested an alternative pathway for the synthesis of DHEA in the central nervous
system involving sterol and/or steroid hydroperoxides. One study in primates reported
high DHEAS levels in the brain that were not strongly suppressed by dexamethasone
treatment, suggesting local biosynthesis (118). Moreover, a postmortem study in human
tissues demonstrated higher levels of DHEA and DHEAS in brain tissue compared to
blood concentration, again suggesting local biosynthesis (119).
Flood et al. were the first to show the memory-enhancing effects of DHEA and
DHEAS, in both young (120-122) and old (123) mice using a foot shock paradigm. In
their extensive studies, multiple routes of administration (i.c.v., s.c., oral) were utilized,
all leading to an inverted U-shaped dose response curve for memory-enhancing effects.
Melchior and Ritzmann (124) demonstrated that when administered i.p., both DHEA and
DHEAS enhanced short-term working memory as assessed with a T-maze paradigm.
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Again, an inverted U-shaped dose response curve was observed. Another group of
experiments demonstrated that DHEAS enhanced memory when given before or directly
after training, but not when administered before retention; suggesting that DHEAS
enhanced the storage and/or consolidation of the learned paradigm but not retrieval (125).
Other studies have investigated the anti-amnestic properties of DHEA(S) using a
variety of amnestic agents. Flood et al. were again the first to show the anti-amnestic
properties of excitatory neurosteroids using multiple routes of administration (120-122).
Maurice et al. confirmed the antiamnestic effect of DHEA and DHEAS in mice utilizing
multiple memory paradigms (Y maze, water maze, passive avoidance) with multiple
amnestic agents (126-128). Moreover, Maurice et al. demonstrated that DHEAS had
effects on learning and/or storing information but no effect on recall of the same
information (127).
DHEA(S) has memory enhancing and anti-amnestic effects on several brain
locations associated with memory function, suggesting a global effect rather than actions
limited to particular structures.

Paradigms utilized to show the memory enhancing

effects of DHEA(S) rely on different neuronal structures, especially the hippocampus, the
amygdala and frontal cortical regions (for review see 129).
Only one study reported memory impairment after DHEAS treatment (130).
DHEAS administered orally for 5 days impaired hippocampal-dependent contextual fear
conditioning, while having no effect on auditory cue fear conditioning.
adrenalectomy,

similar

effects

were

reported,

providing

evidence

Following
for

an

extraglucocorticoid action of DHEA. The results of this experiment could be explained
by a DHEAS-induced potentiation of the corticosterone response to a stressful test
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paradigm, thus shifting the optimal corticosterone response, thereby impairing
hippocampal plasticity. This interpretation is supported by the observations that the
identical DHEAS treatment enhanced memory performance in a T-maze memory
paradigm (a less stressful task of hippocampal-mediated memory in rodents); thereby
demonstrating that the memory impairing effects of DHEAS are only observed if the
hippocampal meditated memory is tested under stressful conditions (131).
Since DHEA(S) concentrations decrease significantly with age in humans and
multiple beneficial effects of DHEAS have been documented in rodents, many studies
have investigated the relationship between DHEA(S) and cognition in humans. Highfunctioning elderly patients, as defined by cognitive and functional examinations, possess
higher DHEAS levels compared to patients in the median or lower functioning groups
(132, 133). Lower DHEAS levels were also associated with poorer health, impaired
global functioning, and physiological well being (134). However, several short term
studies found no beneficial effects of DHEA on well-being or cognitive performance in
old or young adults (135, 136). Recent studies have shown that among Alzheimer’s
disease patients, those with higher concentrations of plasma DHEAS performed better on
tests of association, digit span, and mini mental status exams when compared to those
with lower levels of this neurosteroid (137).
The exact mechanisms by which DHEA(S) enhance memory function in the
rodent remain unclear. It appears that DHEA(S) acts primarily through interactions with
cell surface neurotransmitter receptors. This is in contrast to the classical actions of
steroids that include: binding to an intracellular receptor, translocation to the nucleus, and
binding to a response element resulting in altered protein synthesis. The best documented
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effects of DHEA(S) within the CNS are via negative modulation of the GABAA receptor
complex (138-141).

This ligand-gated ion channel is a multimeric transmembrane

receptor consisting of five subunits arranged around a central pore, which upon
activation, increases chloride influx into the cell. Imamua et al., demonstrated that
DHEA and DHEAS noncompetitively inhibited GABA induced currents in cultured rat
neurons with DHEAS being 3-4 times more potent than DHEA (142). Moreover it was
suggested that DHEAS may interact with the barbiturate sites on the GABAA receptor.
Others have suggested picrotoxin as the DHEAS binding domain with DHEA having no
effects on GABA currents (143). There are several studies in rodents that show that
GABAA antagonists enhance memory (144, 145) and their agonists impair memory (146,
147). These same effects are also relevant to humans, with benzodiazepines impairing
cognition.
In addition to modulating GABAA currents, DHEAS also interacts with sigma
receptors. The sigma receptor (σ1 and σ2) is expressed in many tissue types, but is
particularly concentrated in the CNS (148). Many antipsychotic and antidepressant drugs
have high binding affinity for the receptor (149). Selective sigma agonists potentiate the
response of rat CA3 dorsal hippocampal neurons to N-methyl-D-aspartate (NMDA)
which suggests a functional link between the two receptor types. The ability of sigma
receptors to modulate NMDA mediated glutamatergic neurotransmission has been
emphasized and proposed to play an important role in major neuro-adaptative events,
such as long-term potentiation, learning and memory, and neurodegeneration (149-152).
The first in vitro study for the role of DHEAS in modulating sigma receptors
demonstrated that DHEAS (30mM or higher) potentiated NMDA evoked release of
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norepinephrine from preloaded hippocampal slices (153).

Pertussis toxin, which

inactivates Gi protein function, suppressed this effect of DHEAS (153). Since σ1 but not
σ2 receptors are coupled to Gi proteins, these results suggest that DHEAS modulates the
NMDA response via the σ1 receptor. These conclusions are further supported by a recent
in vivo binding study in mice (154).

Sigma receptor agonists enhanced memory

performance in several paradigms in young as well as in a model for cognitive aging in
rodents (153, 154).

NMDA receptor involvement in memory is suggested by its

important role in the development of long-term potentiation and the finding that NMDA
receptor antagonists produce amnesia in both humans and rodents (143).
There are several possible pathways by which neurosteroids enhance memory
function. The GABAergic neurons of the nucleus accumbens are known to synapse upon
cholinergic neurons of the MS which then form the major cholinergic projections to the
hippocampus (155). Therefore, DHEA(S) may enhance memory by disinhibiting the
cholinergic neurons of the MS and increasing concentrations of acetylcholine in the
hippocampus.

In support of this hypothetical pathway, peripheral administration of

DHEAS enhanced hippocampal ACh release in vivo, and this enhancement occurred in a
dose-dependent manner (155).

In further support of this hypothesis, Yoo et al.

demonstrated a dose dependent increase in hippocampal long term potentiation following
treatment with DHEAS (156).

6. Effects of Steroid Sulfatase Inhibitors on Learning and Memory
There is now good evidence that the metabolism of DHEA and its sulfated form
occurs bi-directionally within the CNS, with DHEAS being desulfated via the enzyme
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steroid sulfatase (108). (p-O-sulfamoyl)-N-tetradeconoyl tyramine (DU-14) is a potent
non-estrogenic irreversible inhibitor of steroid sulfatase. A single dose of DU-14 (30
mg/kg) was able to inhibit 95.2% of the steroid sulfatase activity within the liver (116).
Furthermore, this treatment was able to significantly lower steroid sulfatase activity
within the brain but at a substantially lower rate (14.8% reduction in activity) (116).
Chronic treatments with DU-14 (30 mg/kg for 15 days i.p.) in rodents increased plasma
concentrations of DHEAS, while decreasing plasma DHEA (113). This same treatment
also increased whole brain levels of DHEAS.

Illustration 4: Chemical structure of (P-o-sulfamoyl)-N-tetradeconoyl tyramine

The administration of DU-14 had been shown to increase hippocampal ACh
release, a result which supports the findings that increased DHEAS levels in the brain
augment the levels of ACh within the hippocampus (157).

Additionally, chronic

pretreatment with DU-14 attenuated scopolamine induced spatial memory impairment in
the passive avoidance paradigm and Morris water maze (116, 158). In the Morris water
maze not only did DU-14 reverse the scopolamine induced amnesia, but enhanced the
performance of control animals (116). In agreement with the GABA antagonistic action
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of DHEAS, these findings suggested that DHEAS rather than DHEA was responsible for
memory enhancement. Since all of these experiments administered the steroid sulfatase
inhibitor through an i.p. route, it remains unclear whether the observed effects were
caused by actions of the inhibitor at the peripheral or central level. It was hypothesized
that DU-14 could also attenuate the cognitive deficit associated with lesion of septalhippocampal cholinergic projections.

Illustration 5: Neurosteroid biosynthesis and metabolism in the rat brain. Dotted arrows
indicate metabolic conversion not yet formally demonstrated. Note: figure is a
modification of Figure 1 found in (226)

7. Effects of Aversive Stimulus and Stress on Spatial Learning
Emotional, aversive, and stressful experiences, via the activation of specific
hormonal and brain systems, alter learning and memory processes (159-161). Stress is a
factor that is often overlooked when conducting research with laboratory animals. Stress
31

exposure, depending on intensity and duration, can elicit either positive or negative
effects on cognitive functions, particularly spatial learning and memory performance
(162). Stress-induced responses are largely mediated by the hypothalamic-pituitaryadrenal (HPA) axis and result in increased plasma concentrations of both adrenocorticotropic hormone and corticosterone, released from the anterior pituitary and adrenal
cortex, respectively. Short periods of mild stress (163-164) enhanced acquisition of
certain spatial learning tasks, while longer periods of stress, or corticosterone treatment,
impaired performance on a variety of spatial tasks (165-166).
The ability of stress to enhance performance of a spatial task may be due to the
activation of pathways independent of the septal-hippocampal tract. The glucocorticoids
secreted in response to stress notably bind to mineralcorticoid and glucocorticoid
receptors in the hippocampus. Furthermore, epinephrine released from the adrenal cortex
as a consequence of mild stressors that occur during a memory task can activate
adrenergic receptors that facilitate memory function (167-169). Adrenergic receptors
found on vagal afferents project to the nucleus of the solitary tract and can subsequently
activate neurons that project to the amygdala (164).

The amygdala has long been

associated with the acquisition of memories related to aversive stimuli (170-174) and the
modulation of memory processes of the hippocampus (175-177).
Based on these data, it is hypothesized that the mechanisms and pathways that
underlie stress-induced enhancement of task performance, including spatial memory
tasks, are distinct from the septal cholinergic neurons. It is also hypothesized that the
insertion of an aversive stimulus into a non-aversive DMP task could attenuate the deficit
in acquisition previously observed from the lesion of septal cholinergic neurons. This

32

could explain the lack of consistency in the literature regarding the importance of MS
cholinergic neurons in spatial working memory.

Several studies have shown that

selective destruction of the cholinergic neurons of the MS induced a marked decrease in
acquisition of a spatial task (82, 105, 178). Other investigations, though, have reported
only limited effects of SAP lesions in the MS on spatial tasks. For example, Dornan et
al., (179) reported that a selective reduction of cholinergic transmission in the basal
forebrain was by itself insufficient to account for the functional impairments in spatial
learning of rats using a Morris water maze paradigm. Baxter et al. (180, 181) utilizing a
Morris water maze reported similar findings. Therefore, a task with a mildly aversive
component may preserve acquisition of a spatial task in animals with a septalhippocampal lesion via pathways that are independent of the septal-hippocampal tract.
The result would be a loss of sensitivity in paradigms which involve a mildly aversive
stimulus when assessing impairments in learning/memory associated with septalhippocampal lesion.
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B. Statement of the Problem
Alzheimer’s disease, the most common form of dementia, is a progressive
neurodegenerative disorder characterized by memory loss and behavioral changes.
Decreases in acetylcholine levels in multiple memory systems like the hippocampus and
cortical regions of the brain have been implicated in the pathogenesis of Alzheimer’s
disease. Currently, animal models used to study the effects of cholinergic hypofunction
on learning and memory formation are limited. Animal models must be developed which
can mimic the cholinergic hypofunction seen early in the pathology of many forms of
dementia.

Once these models are developed, detailed studies are needed to determine

the importance of cholinergic projections to the hippocampus and other cortical regions
for learning and memory processes.
The current therapies of choice for dementia are anticholinesterase agents, which
increase synaptic acetylcholine levels by inhibiting the enzyme acetylcholinesterase.
However, these treatments provide only symptomatic relief and are ineffective in treating
the disease itself. DHEAS, a neurosteroid, replacement has been shown to be effective in
reversing memory deficits associated with scopolamine induced amnesia. Furthermore,
preventing the conversion of these neurosteroids, especially DHEAS, to the unsulfated
form can enhance memory function. No study has thus far investigated the effect of
DHEAS treatment on impairments in acquisition of a spatial task due to loss of septalhippocampal cholinergic neurons. Furthermore, it has yet to be determined whether
preventing the conversion of these neurosteroids to the unsulfated form through chronic
administration of a steroid sulfatase inhibitor can attenuate the cognitive deficits
associated with the selective loss of septal-hippocampal cholinergic projections.
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C. Hypothesis and Aims
1. Hypothesis
A selective loss of cholinergic neurons projecting to the hippocampus from the medial
septum results in diminished acquisition of a delayed matching-to-position T-maze
paradigm. DHEAS, through direct administration or prevention of its conversion to an
unsulfated form, will improve acquisition of the delayed matching-to-position T-maze
paradigm independent of cholinergic projections to the hippocampus.

2. Specific aims
1. Examine the changes in the acquisition of a delayed matching-to-position T-maze
paradigm following selective cholinergic immunolesion of the medial septum with 192
IgG-saporin.

2. Examine changes in the adoption of different learning strategies in a spatial T-maze
task following selective cholinergic immunolesion of the medial septum with 192 IgGsaporin.

3.

Examine the ability of DU-14 to attenuate cognitive deficits produced by the

destruction of cholinergic neurons projecting to the hippocampus utilizing delayed
matching-to-position T-maze paradigm.
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4.

Examine the ability of DHEAS to attenuate cognitive deficits produced by the

destruction of cholinergic neurons projecting to the hippocampus utilizing delayed
matching-to-position T-maze paradigm.

5. Examine the effects the introduction of an aversive stimulus into the appetitive Tmaze paradigm has on the acquisition in rats with a selective 192 IgG-saporin lesion of
the medial septum.
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II. MATERIALS AND EQUIPMENT

1. Facilities
Laboratories – Richard King Mellon Hall of Science, Room 416a
Bayer Learning Center, Animal Facility
Office – Richard King Mellon Hall of Science, Room 420

2. Laboratory Animals
300 – 350 gram Male Sprague-Dawley Rats
Hilltop Lab Animals Inc., Scottdale, PA

3. Chemicals and Drugs
192 IgG-saporin
Chemicon, Temecula, CA
Artificial Cerebral Spinal Fluid
CMA Inc., North Chelmsford, MA
Veterinary Sterile Saline
Henry Schein, Melville, NY
Veterinary Sterile Water
Henry Schein, Melville, NY
Pentobarbital
Triadine Solution
Stoelting Co., Wood Dale, IL
Surgilube Surgical Lubricant
Stoelting Co., Wood Dale, IL
Isopropyl Alcohol
Eckerd, Pittsburgh, PA
Ethanol
Fischer Scientific, Pittsburgh, PA
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Mazola Corn Oil
Giant Eagle, Pittsburgh, PA
Acetaminophen
Sigma Chemical Co., Saint Louis, MO
Neosporin Antibiotic Ointment
Lab Safety Supply Inc., Janesville, WI
Dehydroepiandrosterone sulfate
Sigma Chemical Co., Saint Louis, MO
(P-o-sulfamoyl)-N-tetradeconoyl tyramine (DU-14)
Gift from Pui-Kai Li at Ohio State University
Saline Tablets
Sigma Chemical Co., Saint Louis, MO
Ethylenediaminetetraacetic acid (EDTA)
Sigma Chemical Co., Saint Louis, MO
Triton X-100
Sigma Chemical Co., Saint Louis, MO
3

[H] acetyl-CoA
Sigma Chemical Co., Saint Louis, MO
Choline chloride
Sigma Chemical Co., Saint Louis, MO
Physostigmine sulfate
Sigma Chemical Co., Saint Louis, MO
Sodium Chloride
Sigma Chemical Co., Saint Louis, MO
Sodium phosphate buffer
Sigma Chemical Co., Saint Louis, MO
Acetonitrile
Sigma Chemical Co., Saint Louis, MO
Tetrephenylboron
Sigma Chemical Co., Saint Louis, MO
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EconoFluor scintillation cocktail
Packard Instruments, Meriden, CT

4. Materials
Hamilton 7000 5.0 μl Microsyringe
Stoelting Co., Wood Dale, IL
Tungsten Micro Drill
Stoelting Co., Wood Dale, IL
Nylon Monofilament Sutures
Stoelting Co., Wood Dale, IL
Original Perry Style Sterile Surgical Gloves
Stoelting Co., Wood Dale, IL
Surgical Mask
Stoelting Co., Wood Dale, IL
Bouffant Caps
Stoelting Co., Wood Dale, IL
Shoe Cover
Stoelting Co., Wood Dale, IL
NU Gaze
Stoelting Co., Wood Dale, IL
Sterile Cotton Tipped Applicators
Stoelting Co., Wood Dale, IL
Disposable Sterile Surgical Drape
Stoelting Co., Wood Dale, IL
Sterilizing Pouches
Stoelting Co., Wood Dale, IL
Dissecting Forceps
Stoelting Co., Wood Dale, IL
Micro-Dissecting Retractors
Stoelting Co., Wood Dale, IL
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Micro Dissecting Scissors
Stoelting Co., Wood Dale, IL
Bone Ronguers
Stoelting Co., Wood Dale, IL
Needle Holder
Stoelting Co., Wood Dale, IL
Scalpel Blades (#10)
Stoelting Co., Wood Dale, IL
Scalpel Handlers
Stoelting Co., Wood Dale, IL
Pipetman Pipettes
Fisher Scientific, Pittsburgh, PA
BD Falcon Conical Tubes (50, 15 ml)
Fisher Scientific, Pittsburgh, PA
Eppendorf tubes (0.6, 1.5 ml)
Fisher Scientific, Pittsburgh, PA
BioRad Protein Assay
BioRad, Hercules, CA
Scintallation Vials
Fisher Scientific, Pittsburgh, PA
Fisherbrand Redi-Tips disposable pipette tips (200, 1000μl)
Fisher Scientific, Pittsburgh, PA
BD syringe (1.5, 10ml)
Fisher Scientific, Pittsburgh, PA
Disinfecting Cleaner
Lab Safety Supply Inc., Janesville, WI
FEP Tubing
CMA Inc., North Chelmsford, MA
Infusion Probe
CMA Inc., North Chelmsford, MA
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Reward Pellets
Research Diets, New Brunswick, NJ
LabDiet Rodent Chow
Purina Mills, St. Louis, MO

5. Equipment
Accumet pH Meter, Model 291
Fisher Scientific, Pittsburgh, PA
Themolyne Nuova Stirrer
Fisher Scientific, Pittsburgh, PA
Fisher Scientific Accu-124 Scale
Fisher Scientific, Pittsburgh, PA
Revco Freezer (-80°C)
Revco Thermo Electron Corporation, Asheville, NC
Whirlpool Refrigerator
Whirlpool Corp., Benton Harbor, MI
Autoclave
Lab Standard Stereotaxic Instrument
Stoelting Co., Wood Dale, IL
Infusion Syringe Pump
Stoelting Co., Wood Dale, IL
Germinator Dry Sterilization
Stoelting Co., Wood Dale, IL
Rodent Brain Matrices (large coronal rat)
Stoelting Co., Wood Dale, IL
Decapitator
Stoelting Co., Wood Dale, IL
Homeothermic Blankek for Rodents
Stoelting Co., Wood Dale, IL
Surgical Clippers
Stoelting Co., Wood Dale, IL
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Rotating T-Maze
Consists of: Approach alley: 4” wide x 14” long
Two Goal Arms: 4” wide x 12” long
Black acrylic walls 5” high
Clear acrylic hinged top
Mounted to a “Lazy Susan”
Sonicator
Fisher Scientific, Pittsburgh, PA
Liquid Scintillation Counter
Packard Instruments, Meriden, CT
UV/VIS Spectrophotometer
Beckman Instruments, Fullerton, CA
6. Computer Software
Graphpad Prism 3.0
Graphpad, San Diego, CA
Microsoft Excel, Microsoft Office XP
Microsoft Corporation, Orem, UT
Microsoft Word, Microsoft Office XP
Microsoft Corporation, Orem, UT
Microsoft Photoshop, Microsoft Office XP
Microsoft Corporation, Orem, UT
Microsoft PowerPoint, Microsoft Office XP
Microsoft Corporation, Orem, UT
Adobe Photoshop Version 5.0
Adobe Sytems, Seattle, WA
Adobe Acrobat (Reader and Writer)
Adobe Sytems, Seattle, WA
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III. EXPERIMENTS
A. Effects of medial septum cholinergic lesions on ChAT activity.
1. Introduction
SAP is a powerful immunotoxin that has been shown to selectively destroy the
p75 NGF receptor expressing neurons that are extensively expressed on the soma and
terminals of the cholinergic neurons of the basal forebrain (75,77).

Histological

experiments demonstrated that localized infusion of SAP into the three distinct loci of the
basal forebrain resulted in a complete loss of NGF immunoreactive neurons within the
area of interest (80).

Following localized infusions of SAP, sections stained for a

cholinergic marker, AChE, showed a loss of cholinergic neurons in the distinct loci.
Furthermore, there was a dramatic reduction of AChE staining in the target areas
(dorsolateral neocortex, cingulated cortex, and hippocampus) associated with these
distinct loci of the basal forebrain.

Similarly, ChAT activity in the targeted areas

displayed reduced activity, further demonstrating decreased cholinergic innervation (81).
Smaller doses of SAP (0.22 μg) injected directly into selected loci of the basal forebrain,
like the MS, spared not only the purkinje fibers but also GABAergic neurons present in
the MS (82).

Therefore, we hypothesized that low doses of SAP can be used to

selectively destroy the cholinergic neurons of the MS. We evaluated whether infusions
of SAP (0.22 μg) into the MS significantly lowered the ChAT activity in the
hippocampus, while displaying no effect on frontal cortex ChAT activity. These results
will validate the selective loss of cholinergic neurons present in the MS and the sparing
of the cholinergic neurons in the NBM following the SAP infusion. ChAT activity in the
hippocampus and frontal cortex was also used to determine correct placement of the
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cannula during the SAP lesioning process. We predicted that small dose of SAP (0.22
μg) infused directly into the MS will result in complete loss of cholinergic innervation of
the hippocampus from the MS. Infusions of small doses of SAP can then be used as a
model to explore the importance of the MS cholinergic innnervation of the hippocampus
in different learning and memory tasks. SAP treated animals that did not show selective
loss of ChAT activity in the hippocampus were excluded from subsequent studies.

2. Methods
i. 192 IgG-saporin Immunolesioning:
All experiments followed the guidelines of the N.I.H. for the care and use of
laboratory animals and were approved by the Duquesne University Institutional Animal
Care and Use Committee. Male Sprague-Dawley rats weighing between 300 and 350
grams were obtained from Hilltop Lab Animals (Scottdale, PA). Male rodents were
chosen so that influences of estrogens on learning and memory were minimized.
Animals were housed individually in a temperature and humidity controlled facility on a
12:12 h light:dark cycle with unrestricted access to food and water. For intraseptal
infusion, animals were anesthetized with pentobarbital (50mg/kg; IP) and placed into a
stereotaxic frame. An incision was made exposing the dorsal aspect of the skull and a
hole was drilled over the medial septum (MS; +0.2 bregma, 0.0 lateral). A stainless steel
cannula was lowered 5.6mm from the dura into the MS. Animals were infused with
either 1 μl vehicle (artificial cerebral spinal fluid [aCSF]) or SAP (0.22μg in 1 μl of
aCSF) over 5 min. at a rate of 0.2μl/min. The dose of SAP was selected based on
previous studies using the same lot number (Advanced Targeting Systems; Lot #24-87)
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that demonstrated a substantial loss of cholinergic neurons in the MS with little
nonselective damage to GABAergic neurons (82).

Following infusion, the cannula

remained in place for 5 min. to allow for diffusion of the solution into the tissue, and
prevent the removal of SAP from the intended injection site. The incision was sutured
closed and animals were allowed to recover for 2 weeks before initiating behavioral
testing.

ii. Choline Acetyltransferase Assay (ChAT):
The degree of cholinergic deafferentation was assessed by measuring ChAT
activity within the hippocampus and frontal cortex.

After completing all training,

animals were anesthetized with pentobarbital (100mg/kg; IP) and perfused with ice cold
saline. The brains were removed, and tissues from the hippocampus and frontal cortex
dissected, frozen, and stored at -80°C until processed for ChAT activity as previously
described (82). Frozen tissues were thawed and dissociated by sonication in a medium
containing EDTA (10mM) and Triton X-100 (0.5%) and diluted to a concentration of
10mg tissue/ml. An aliquot of each sample was used for the determination of total
protein (186). Three 5μl aliquots of each sample were incubated for 30 min. at 37°C in a
medium containing 3[H] acetyl-CoA (50,000-60,000d.p.m./tube, final concentration
0.25mM acetyl-CoA), choline chloride (10.0mM), physostigmine sulfate (0.2mM), NaCl
(300mM), sodium phosphate buffer (pH 7.4, 50mM), and EDTA (10mM). The reaction
was terminated with 4 ml sodium phosphate buffer (10mM) followed by the addition of
1.6mL of acetonitrile containing 5mg/ml tetraphenylboron.

The amount of 3[H]

acetylcholine produced was determined by adding 8 ml of EconoFluor scintillation
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cocktail and counting total cpms in the organic phase using an LKB beta-counter.
Background was determined using identical tubes to which no sample was added. The
three reaction tubes containing sample were averaged and the difference between total
cpms and background cpms was used to estimate the total amount of ACh produced per
sample. Cholineactyltransferase activity was then calculated for each sample as pmol
Ach synthesized/hr/μg protein.

iii. Statistical Analysis:
Due to the large number of samples, ChAT assays were completed with multiple
runs, with each run containing samples from different treatment groups and normalized to
percent change from controls. Differences in ChAT activity for the hippocampi of
treatment groups were determined using one-way ANOVA. All analyses were performed
using GraphPad Prism 3.0.

3. Results
Levels of ChAT activity are summarized in Table 1a and 1b. As expected,
infusion of SAP (0.22μg/μl) into the medial septum (MS) resulted in a significant
decrease in ChAT activity within the hippocampus, demonstrating a loss of cholinergic
afferents from the MS to the hippocampus. There was a 70.5% decrease in ChAT
activity in the hippocampi of SAP-MS treated rats compared to control animals. (7.85 ±
1.37 versus 26.61 ± 0.77 pMol ACh/h/μg protein; p < 0.001). There was no significant
difference in ChAT activity between treatment groups for tissues collected from the
frontal cortex (p = 0.26).
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Table 1a: ChAT activity in aCSF-treated control animal
Range
Means ± s.e.m.
Hippocampus (n=45)
25.03 – 31.10
26.61 ± 0.77
Frontal Cortex (n=45)
27.21 – 40.92
34.12 ± 3.06
Values expressed as pMol ACh produced/h/μg protein.
Table 1b: ChAT activity in SAP-MS treated animal
Range
Hippocampus (n=42)
3.83 – 13.34
Frontal Cortex (n=42)
22.24 – 44.83
Values expressed as pMol ACh produced/h/μg protein.

Means ± s.e.m.
7.85 ± 1.37
30.01 ± 3.62

4. Discussion
The ChAT assay results demonstrated that infusion of SAP (0.22μg/μl) into the
MS resulted in a significant decrease of ChAT activity within the hippocampus, but not
in the frontal cortex (Table 1a-1b). This finding is consistent with previous studies that
showed a substantial loss of cholinergic neurons in the medial septum, but not in the
nucleus basalis magnocellularis (NBM) using the same infusion protocol (82, 187, 188).
The selectivity of SAP for cholinergic neurons in the MS has been questioned. High
doses of SAP injected into the lateral ventricles led to the loss of non-cholinergic
p75NTR-expressing neurons located in distal from the infusion site (197). Many of these
distal effects were avoided by infusing small amounts of SAP directly into the MS. Since
GABAergic innervation of the hippocampus plays an important role in regulating
hippocampal function it is important to select a dose of SAP that will not affect other
neuron types at the site of infusion. Parvalbumin is a calcium binding protein that serves
as a marker for GABAergic neurons.

Previous studies have shown that the dose

(0.22μg/μl) from the lot of SAP used in the present study had little effect on GABAergic
parvalbumin-containing neurons located in the same regions of the MS (82). Therefore,
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it is concluded that any learning deficits observed in SAP treated groups are the
consequence of a selective septal-hippocampal cholinergic lesion. SAP treated animals
that did not display selective destruction of the MS cholinergic neurons were eliminated
from all subsequent experiments.

B. Effects of medial septum cholinergic lesions on spatial performance.
1. Introduction
To study the contributions of cholinergic basal forebrain neurons to the
establishment of the cognitive features of AD, animal models are required that
specifically mimic cholinergic cell loss in the basal forebrain and cortical cholinergic
hypoactivity.

This experiment was designed to better understand the role of the

cholinergic projections from the MS during learning and memory. Several studies have
shown that selective destruction of the cholinergic projections from the MS induced a
marked decrease in acquisition of a spatial task (82, 105, 178).

However, other

investigations have reported only limited effects of SAP lesions in the MS on spatial
tasks. For example, Dornan et al., (179) reported that a selective reduction of cholinergic
transmission in the basal forebrain was by itself insufficient to account for the functional
impairments in spatial learning of rats using a Morris water maze paradigm. Baxter et al.
(180, 181) utilizing a Morris water maze reported similar findings. It is possible that
other tests may be more sensitive for detecting cognitive deficits associated with the
selective loss of cholinergic projections from the MS, particularly tests which assess
learning as opposed to working memory and retention. We hypothesized that a selective
loss of cholinergic neurons projecting to the hippocampus from the MS results in
diminished acquisition of a DMP T-maze paradigm. We predict that SAP treated animals
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will take significantly more days to reach criterion and acquire the DMP task at a
significantly slower rate. If learning and memory deficits are observed following SAP
lesioning of the MS, this could serve as a model to test drug therapies targeted at
attenuating these memory deficits. Furthermore, this can be used as a model to determine
the importance of the MS cholinergic neurons in AD pathology.

2. Methods
Immunolesioning of the cholinergic neurons of the MS with SAP was performed
as documented in Experiment A. All animals were allowed to recover 2 weeks following
surgery before initiation of the behavioral testing. Following behavioral testing ChAT
activity in the hippocampus and frontal cortex was determined for each animal as
described in Experiment A. SAP treated animals that did not show selective decrease in
ChAT activity within the hippocampus were eliminated from the study.

i. Dietary RestrictionFollowing surgery animals remained on an ad libitum diet. The day before the
first session of T-maze acclimation, all food was removed from the housing cages. Diet
restrictions began by feeding the animals 4 pieces of Rodent Chow (~8 g) after
completion of the T-maze acclimation.

Weight was monitored daily, adjusting the

amount of chow so that the animal maintained ~85% of normal body weight throughout
the study. A control animal fed ad libitum was included with each experimental group to
ensure that the weights of the experimental animals did not exceed 85% of a normal age
matched controls.

Animals were fed after completion of T-maze activities.
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ii. Behavioral testing:
The delayed match-to-position (DMP) task was performed as recently described
(82, 182, 183). All behavioral testing was performed between 10:00 a.m. and 2:00 p.m.,
seven days a week, except following the introduction of the probe trial. During the probe
trial a morning session (9:00 a.m. to 12 p.m.) and afternoon session were both performed
(2:00 p.m. to 5 p.m.). The order of testing for the different groups of animals was
changed daily. DHEAS displays minimal variation in plasma concentration associated
with circadian rhythm, while DHEA has a short serum half-life and serum concentrations
that fluctuate markedly with the circadian rhythm (86-90). Varying the order by which
the animals were tested minimizes the impact that variations due to circadian rhythms of
DHEA and other neuroactive steroid levels has on learning and memory.

T-maze Acclimation:
Acclimation began by scattering ten reward pellets throughout the T-maze with
all doors of the T-maze opened. Randomly paired animals were placed into the T-maze
for 10 minutes. Before running the next pair of animals, the T-maze was cleaned with a
non-toxic spray disinfectant.
On the second day of acclimation, ten reward pellets were scattered throughout
the T-maze and all doors of the T-maze remained open. Sweetened rodent chow (50 mg,
sucrose sweetened chow) was used throughout all experiments as the reward pellet.
Animals were placed individually into the T-maze for 5 minutes. Again, the T-maze was
cleaned with a non-toxic spray disinfectant following each acclimation session.
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On days three through five of acclimation, four reward pellets were placed in each
goal arm of the T-maze (total of 8 pellets) and all doors of the T-maze remained open.
Animals were placed individually into the T-maze for 5 minutes or until all 8 pellets were
eaten.
Animals were then trained to run to the ends of each goal arm by using a series of
6 forced choices on days six through eight of acclimation. Animals were placed
individually into the start box of the T-maze with the approach alley door and one goal
arm door closed. After 10 seconds of confinement in the start box, the approach alley
door was opened, allowing the animal to explore the maze. Once the animal entered the
open goal arm, 2 reward pellets were dropped into this arm. The animal was allowed to
explore the T-maze for 90 seconds or until both reward pellets were eaten. After each
trial pair, animals were returned to their housing cages for 5-10 minutes, while training
proceeded on the remaining animals of the group. To avoid the introduction of a side
bias, right and left goal arms were alternated in a random and balanced fashion according
to the below list.

DAY 6
Left
Right
Left
Right
Left
Right

DAY 7
Right
Left
Right
Left
Right
Left
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DAY 8
Left
Left
Right
Right
Left
Right

Delayed Match-to-Position Task Testing:
The DMP task was chosen to offset the natural tendency for spontaneous
alternation observed in rodents (184, 185). Animals were placed individually into the
start box of the T-maze with the approach alley door and one goal arm door closed. After
10 seconds, the approach alley door was opened allowing the animal to move out of the
start box and down the alley. Once the animal entered the open goal arm, 2 reward
pellets were placed in the arm. The animal was allowed to explore the T-maze for 1
minute or until both reward pellets were eaten.

The animal was then immediately

returned to the start box and the maze was cleaned with nontoxic disinfectant spray to
remove any odor cues. Both goal arm doors were opened followed by the approach alley
door. The rodent was allowed to explore the T-maze for 1 minute or until it entered a
goal arm. If the animal entered the same physical goal arm (correct choice) that it
explored during forced choice, 4 reward pellets were placed in the arm. After the animal
had eaten the pellets, it was returned to its housing cage for 5 to 10 minutes while training
on the remaining animals in the group was finished. If the animal entered the opposite
goal arm (incorrect choice) as sampled during the forced choice, the goal arm door was
closed and the animal was confined to that goal arm for 30 seconds. After the 30 seconds
of confinement, the animal was returned to its housing cage for 5 to 10 minutes while
training on the remaining animals in the group was finished. Animals continue to receive
eight trials per day until a criterion of 15 correct choices out of 16 consecutive trial pairs
were met.
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The following is the pattern in which all animals were run during DMP acquisition.
DAY 1: Left
Left
Right
Right
Left
Left
Right
Right

DAY 2: Right
Left
Right
Left
Right
Left
Right
Left

DAY 3: Right
Left
Right
Left
Right
Left
Left
Right

DAY 4: Right
Right
Left
Left
Right
Right
Left
Left

DAY 5: Left
Right
Left
Left
Right
Left
Right
Right

DAY 6: Right
Left
Left
Right
Left
Right
Left
Right

DAY 7: Left
Right
Right
Left
Right
Left
Left
Right

DAY 8: Left
Left
Right
Right
Left
Right
Left
Right

DAY 9: Right
Left
Right
Left
Right
Right
Left
Left

DAY 10: Right
Left
Right
Left
Left
Right
Right
Left

DAY 11: Left
Right
Right
Left
Right
Right
Left
Left

DAY 12: Right
Right
Left
Left
Right
Left
Left
Right
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DAY 13: Right
Right
Left
Right
Left
Left
Right
Left

DAY 14: Left
Left
Right
Left
Right
Left
Right
Right

DAY 15: Left
Right
Right
Left
Left
Right
Left
Right

DAY 16: Left
Right
Left
Right
Right
Left
Left
Right

DAY 17: Right
Left
Right
Left
Left
Right
Left
Right

DAY 18: Left
Left
Right
Right
Left
Right
Right
Left

DAY 19: Left
Right
Right
Left
Left
Right
Right
Left

DAY 20: Left
Left
Right
Left
Right
Right
Left
Right

DAY 21: Right
Right
Left
Right
Left
Right
Left
Left

DAY 22: Left
Right
Left
Right
Right
Left
Right
Left

DAY 23: Right
Left
Left
Right
Left
Right
Right
Left

DAY 24: Right
Left
Right
Right
Left
Right
Left
Left

DAY 25: Right
Left
Left
Right
Right
Left
Right
Left

DAY 26: Left
Right
Left
Left
Right
Right
Left
Right

DAY 27: Right
Left
Right
Right
Left
Left
Right
Left
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DAY 28: Left
Right
Left
Right
Left
Right
Left
Right

DAY 29: Right
Left
Right
Right
Left
Left
Right
Left

DAY 30: Right
Left
Left
Right
Right
Left
Left
Right

iii. Statistical Analysis:
Days to criterion were analyzed using Student's T-test for individual comparisons
of the two treatment groups. To compare treatment effects during different stages of
acquisition, performance data was blocked into 3-day periods of training. After an
animal had reached criterion, a value of 93.75% (15/16) was recorded for performance on
subsequent days. Performance during acquisition testing was analyzed using two-way
ANOVA for overall effects of block and treatment and Student's T-test for treatment
effects within blocks. Both the rate of performance and days to reach criterion in the
DMP t-maze task was determined to be parametric. Power analysis and variability seen
in similar studies (82, 188) suggests that 8 animals per treatment group were enough to
determine statistical significance. All analyses were performed using GraphPad Prism
3.0.

3. Results
Of the original 19 animals, all but two animals failed to reach criterion on the
delayed matching to position (DMP) task or displayed a side bias and were excluded
from the study. One of the two animals was an aCSF control animal while the other
received SAP lesioning of the MS. Analysis of the remaining animals (8 control animals
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and 9 SAP) indicated that SAP treated animals required more days to reach criterion (Fig.
1). Control animals took an average of 16.00 ± 1.195 days while the animals that
received SAP lesioning of the MS took an average of 21.56 ± 3.779 to complete the DMP
task. Mann-Whitney non-parametric U-test showed a significant effect on treatment (p =
0.001), indicating that SAP treated animals differed significantly from the aCSF treated
control animals.
Examining of the learning curves (Fig. 2) showed that all animals performed at
similar levels, below chance, at the start of DMP training and SAP treated animals
improved at a slower rate when compared to aCSF-treated controls. Analysis of the
learning curves by two-way ANOVA demonstrated a significant effect of “Treatment”
(F[1,490] = 64.10, p < 0.0001), a significant effect of “Block” (F[9,490] = 159.82, p <
0.0001 ), and a significant ‘Tretament’ X ‘Block’ interaction (F[9,490] = 7.86, p =
0.0001).

A separate analysis of performance within a block revealed aCSF-treated

animals performed significantly better than SAP treated animals during blocks 4-7 of
training.
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Number of Days to Criterion

30
25

*

20
15
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SAP-MS
(n=9)

(n=8)

Figure 1. Effects of SAP-lesion of the MS on the number of days to reach criterion
in the DMP T-maze task.
Bar graph of days to reach criterion in the DMP T-maze task. Top of bar represents the mean
number of days to reach criterion ± standard error of the mean. Note that SAP-MS treated
animals required significantly more days to reach criterion than the aCSF- treated controls. * p <
0.05 relative to the aCSF-treated control animals.
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Figure 2. Effects of SAP-lesion of the MS on the rate of acquisition in the DMP Tmaze task.
Learning curves show the effects of SAP lesioning of MS on the rate of DMP acquisition. Points
represent the mean percentage correct for each treatment group during a 3 day period of training.
By day 21 of training, all control animals had reached criterion, and only four of nine SAP treated
animals had reached criterion. By day 30 all animals had reached criterion. Note that both
groups showed improved rates of performance over time; however, during blocks 4–7 the rate of
performance of the SAP treated animals was significantly impaired compared to the control
animals. ** p < 0.0001, * p < 0.05 for aCSF treated control animals relative to each of the SAP
treated groups.

58

4. Discussion:
The behavioral results show that SAP treated animals were significantly impaired
in the acquisition of the DMP task. Specifically SAP treated animals took significantly
longer to reach criterion and improved at a slower rate compared to controls (Fig. 1, 2).
The specific cognitive processes disrupted following SAP lesion of the MS still remain
unknown.
The motor activity of the different treatment groups during the acclimation phase
of the DMP T-maze task suggests that there is no change in the motor activity following
the SAP infusion. Both treatment groups could readily transverse the maze and obtain
the reward pellets. Furthermore, there was no difference in the ability of SAP treated
animals to explore an open field as compared to aCSF treated controls. This suggests that
the decrease in the rate of acquisition and the increase in days to reach criterion was not
influenced by the motor activity of the different treatment groups.
Several studies have reported limited to no effects of SAP lesion of the basal
forebrain on tests of spatial working memory in rats. Mild working memory deficits
were reported using a delayed non-matching to sample radial arm maze following SAP
lesion of the MS (189). No deficits in memory recall were reported in rats that acquired a
spatial paradigm followed by SAP lesioning of the MS and retesting (190). Likewise,
there was no reported effect of SAP lesion of the MS, NBM, or MS plus NBM on spatial
working memory in the Morris water maze (179-181). Moreover, Cahill and Baxter
(191) reported facilitated acquisition of a discrimination task following SAP-lesions to
the MS, suggesting no deficit in spatial working memory. No significant performance
differences were reported between SAP lesions of the MS or control rats when the
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intertrial delay between the forced and open choice was increased in the DMP task once
animals reached criterion (82,188). Together, these findings suggest that any spatial
working memory deficit produced by selective loss of the septal-hippocampal cholinergic
neurons is mild at best, and not likely to account for the diminished acquisition of the
DMP task following SAP lesion of the MS.
Other reports suggest that cholinergic neurons of the basal forebrain are more
important for attentional processes than working memory processes.

For example,

several studies have reported significant deficits on tests of visual attention following
SAP lesions of the NBM (192-194). Cholinergic projections from the MS were less
involved in visual attention processes (195), but may influence other attentional processes
important in acquisition of a spatial task.
Rats have a natural tendency for spontaneous alternation, which affects
performance on spatial alternation tasks (184, 185). In a simple alternation task, many
rats performed better than chance on the first day of acquisition (184, 185). As a result, it
is often difficult when using a simple alternation paradigm to assess the rate of
acquisition and overall performance of the animals. It was reported that infusions of SAP
into the NBM of rats had no effect on the acquisition of a T-maze alternation task (196).
Examination of the learning curves showed that the performance of control animals was
near criterion, and that SAP lesioned animals performed better than chance at the
beginning of training. Employing a T-maze alternation task, therefore, would make any
effect on learning difficult to assess.

By utilizing the DMP paradigm, the natural

tendency of rats to alternate is opposed, thereby increasing the initial difficulty of the task
and the sensitivity of the task to detect changes in task acquisition. This was evident on
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the first day of training, where both the control and SAP lesioned rats perform below
chance (Fig. 2). Following day 1 of training, the performance of all animals improved
with control animals quickly surpassing the rate of acquisition for SAP lesioned rats. The
DMP paradigm provided a sensitive behavioral assay for revealing selective deficits in
the septo-hippocampal cholinergic pathway, while the specific cognitive process
underlying the decreased rate of acquisition remained unclear. One of the most popular
theories for the role of the hippocampus states that a map of the environment is built up
in the hippocampus and serves to guide the animal within its environment (197).
According to this theory, animals with hippocampal hypofunction are unable to use
spatial strategies (based on a cognitive map), but can use either an orientation or guidance
strategy, which are mediated by non-hippocampal structures. A possible explanation for
the decreased rate of acquisition could be a decrease ability to use a spatial strategy or
greater reliance on another learning strategy.

C. Effects of medial septum cholinergic lesions on learning strategies.
1. Introduction
Recently, investigations utilizing the selective cholinergic immunotoxin 192-IgG
Saporin (SAP) have found that lesioning cholinergic neurons of the MS has little or no
effect on working memory in tests such as the Morris water maze (179, 180, 190).
However, as documented in Experiment B this same lesion significantly delays
acquisition of a DMP T-maze task. Rats can utilize a number of different strategies to
solve spatial tasks (for a review, see (27)). For example, an animal may utilize a
consistent directional body turn to navigate a maze using either egocentric or allocentric
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cues, or a spatial strategy that relies on the location of extra maze visual cues (198-200).
Evidence suggests that turning strategies rely primarily on striatal circuits whereas spatial
strategies rely more on hippocampal circuits (198, 200-202). As an example, when the
dorsal hippocampus was inactivated via an infusion of lidocaine, use of a place strategy
was inhibited (199). Conversely, following stimulation of the dorsal hippocampus with
glutamate, rodents preferentially chose a place learning strategy (199).

Therefore,

another mechanism by which MS cholinergic lesions could affect DMP acquisition
independent of working memory is by affecting the use and/or preservation of a place or
response strategy.

The purpose of this study was to test the hypothesis that MS

cholinergic lesions impair DMP acquisition in male rats by causing alterations in the
adoption and/or preservation of the learning strategies used within the DMP task. We
predicted that SAP treated animals will use a persistent turning strategy for significantly
more days, influencing the number of days the animal needs to reach criterion in the
DMP task and the rate of acquisition for the task.

2. Methods
Immunolesioning of the cholinergic neurons of the MS with SAP was performed
as documented in Experiment A. Following behavioral testing ChAT activity in the
hippocampus and frontal cortex was determined for each animal as described in
Experiment A. SAP treated animals that did not show selective decrease in ChAT
activity within the hippocampus were eliminated from the study.
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i. Post-criterion Spatial Manipulation:
Fourteen days after surgery for SAP infusion, animals were food deprived to 85%
of their normal body weight and then acclimated to the T-maze as described in
Experiment B. Acquisition of the DMP task, described in Experiment B, continued until
two stages of learning were established. One group of animals (criterion performance)
received eight trial pairs per day until the animals acquired the DMP paradigm, defined
as 15 correct choices out of 16 consecutive trial pairs, while another group (response like
performance) received training until 15 out of 16 entries into the same goal arm was
observed. Once either criterion was reached, spatial manipulation was introduced into
the testing procedure. During a morning session animals were run as described for the
DMP task. During the afternoon session, animals completed the forced choice, but
before the second open choice of the trial pair, the maze was rotated 180º. The animals
were then placed in the start box and allowed to complete the second part of the trial pair.
Use of a response like strategy was defined as entering the same physical goal arm in at
least 7 out of 8 trials per day. A place strategy was defined as returning to the goal arm
located in the same location within the testing environment 7 out of 8 times.

ii. Statistical Analysis:
During the course of DMP training it was observed that throughout early stages of
training, many animals adopt a turning strategy whereby they consistently turned to the
right or left goal arm of the maze. To quantify this observation, we counted the total
number of days the animals utilized the strategy during the testing process. Any animal
that entered 7 out of 8 times into the same goal arm was defined as using a turning
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strategy. A student T-test was used to analyze the number of animals that adopted this
strategy and also the number of days that an animal utilized the strategy. To evaluate the
contribution that the turning strategy had on the number of days to reach criterion, the
duration of the turning strategy was subtracted from the overall days to criterion from
each animal and analyzed with a student T-test. Effects of rotating the maze 180°
between the open and forced chioce were analyzed by ANOVA comparing the
performance during a normal morning session with performance in an afternoon session
when the maze was rotated.

Performance and days to criterion were analyzed as

parametric data.
One goal of the research was to test the predictions about the relationship between
cholinergic activity in different brain regions and the different learning strategies adopted
by each treatment group. ChAT activity was used to measure the cholinergic activity
with in the hippocampus and frontal cortex. To compare the number of days with a
turning strategy and ChAT activity, a scatter plot was developed and analyzed utilizing a
Spearman’s Rho correlation between groups and within groups.

All analyses were

performed using GraphPad Prism 3.0.

3. Results
Animals appeared to adopt different learning strategies at different times during
training of the DMP task. To determine changes in learning strategies, a probe trial was
introduced once animals reached two different stages of learning. We observed that
during the early stages it appeared that animals adopted a turning strategy, where animals
entered the same arm during the open trial no matter which arm they entered in the forced
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trial. Therefore, the criterion for the first stage of learning that was examined was
defined as 15/16 turns into the same arm of the T-maze as during the open trial. Prior
observations have shown that animals reach this criterion early in training (days 3-6).
The second stage of learning was followed by additional training when an animal reached
the DMP criterion, defined as 15/16 correct choices (days 16-24). After reaching either
criterion, each rat received a probe trial over three consecutive days during which the
maze was rotated 180° (relative to the extra-maze cues) between the forced and open
trials. Animals using extra-maze cues would enter the arm in the same location of the
room as previously visited. This would be the opposite arm visited during the forced
trial, thus an incorrect choice. Animals relying on internal cues would be expected to
enter the same physical arm of the T-maze entered during the forced trial no matter the
orientation of the maze in the testing room: a correct choice.
A probe trial introduced during the earlier stage of learning had no significant
effect on the performance (Fig. 3A–3B) of either aCSF-treated controls or SAP treated
animals. During a morning session of normal DMP training, aCSF treated animals
displayed an average performance of 47.40 ± 1.06% correct, compared to the probe trial
when animals displayed an average performance of 50.00 ± 1.51% correct. SAP treated
animals also displayed similar behavior with an average performance of 48.75 ± 0.86%
correct during normal DMP training and an average performance of 49.38 ± 2.31%
correct during the probe trial.
Since animals seemed to adopt a turning strategy at this early stage in training, the
number of times an animal entered a single arm of the T-maze during the open trial was
also examined. The probe trial introduced during this stage of learning had no significant
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effect on the established turning strategy for either the aCSF treated or SAP treated
animals (Fig. 4A–4B). During the morning session of normal DMP training, the aCSF
treated animals averaged 7.83 ± 0.08 turns into a single goal arm of the T-maze during
the open trial, compared to the probe trial when these same animals averaged 7.46 ± 0.19
turns into the same arm. SAP treated animals displayed similar behavior. During a
normal training session SAP treated animals averaged 7.86 ± 0.14 turns into a single arm
during the open trial, compared to the probe trial when these same animals averaged 7.71
± 0.28 turns into the same arm. The performance and entry patterns suggest that during
this stage of learning, rotating the maze had no effect on arm choice in each of the
treatment groups. This result indicates that during the early stages of learning, neither
treatment group used extra-maze cues to a significant degree to navigate the maze.
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Figure 3A - 3B. Effects of rotating the T-maze on performance of animals using
persistent turning strategy.
The performance of aCSF treated control animals (n=8) and SAP treated animals (n=6) during a
normal trial pair (days 1a – 3a) and the probe trial (days 1b – 3b) over three consecutive days.
Performance during the early stages of training when animals exhibited a turning strategy as
defined by 15/16 turns to the same arm. The bars represent the mean percentage correct ± s.e.m.
Note that introducing a probe trail had no significant effect on performance of either aCSF treated
controls or SAP treated animals.
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Figure 4A – 4B. Effects of rotating the T-maze on entry patterns of animals using a
persistent turning strategy.
Scatter plots showing entry patterns for aCSF treated control animals (n=8) and SAP treated
animals (n=6) during a normal trial pair (day1a-3a) and the probe trial (day1b-3b) over three
consecutive days. Entry patterns summarized is during the early stages of training when animals
exhibited a turning strategy defined by 15/16 turns to the same arm. The line in the middle
represents the mean ± s.e.m. Note that introducing a probe trail had no significant effect on
entries into a single arm of the T-maze for either aCSF treated controls or SAP treated animals.
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A probe trial introduced following additional DMP training had a significant
effect on the performance for both aCSF treated and SAP treated animals that had
reached criterion in the DMP task (Fig. 5A–5B). During three consecutive days of the
probe trial, the average performance was 53.13 ± 3.63% for aCSF treated controls and
63.02 ± 2.76% for SAP treated animals.

These values differed significantly from

performance during the normal training session (93.23 ± 2.13% for aCSF treated
controls; 94.27 ± 1.50% for SAP treated animals; p < 0.001 for all days). Changes in
performance indicated that following additional training, rotating the maze disrupted arm
choice for both treatment groups. This result indicated that for the rats to solve the Tmaze DMP paradigm they relied on extra-maze cues when making an arm choice.
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Figure 5A – 5B. Effects of rotating the T-maze on animals that have reached
criterion following extensive training.
The performance of aCSF treated control animals (n=8) and SAP treated animals (n=8) during a
normal trial pair (days 1a – 3a) and the probe trial (days 1b – 3b) over three consecutive days.
Performance summarized is following extensive training when animals have solved the maze and
chose 15/16 correct.

The bars represent the mean percentage correct ± s.e.m.

Note that

introducing a probe trail significantly decreased the performance of both aCSF treated controls
and SAP treated animals. *** p < 0.001 relative to the normal trial pair (days 1a – 3a).
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As mentioned above, we observed that during early stages of training many of the
animals adopted a turning strategy. Of the eight aCSF treated control animals, six
developed a turning strategy (75%), defined as 15/16 turns to the same goal arm. All
nine SAP treated animals adopted the turning strategy (100%). There was no significant
difference in the number of days before each of the groups of animals adopted the turning
strategy. aCSF treated controls took an average of 4.5 ± 1.6 days to adopt this learning
strategy while SAP treated animals took an average of 4.7 ± 0.9 days. The number of
days that animals engaged in the turning strategy was significantly greater for rats with
SAP lesion of the MS (Fig. 6). SAP treated animals engaged in a turning strategy for
14.33 ± 1.81 days while aCSF treated controls engaged in this strategy for 6.63 ± 1.71
days.
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Figure 6. Number of days animals were engaged in a persistent turning strategy
during DMP training.
The number of days rats displayed a turning strategy during DMP T-maze training. Line
in the middle represents the mean ± s.e.m. Note that SAP treated animals adopted a
turning strategy for more days when compared to controls. ** p < 0.01 relative to the
aCSF treated controls.
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To determine whether the percentage of animals that adopted the turning strategy
had any significant effect on the analysis of the number of days animals engaged in the
turning strategy, those animals that never adopted a turning strategy were excluded.
After excluding these animals, there was still a significant difference between SAP
treated animals and aCSF treated controls (Fig. 7), suggesting that at least some of the
difference was due to an increased utilization of the turning strategy following SAP
lesioning of the MS.
To determine whether the differences in the number of days rats were engaged in
a turning strategy was enough to explain the effects of treatment differences on
acquisition of the DMP task, the days using the turning strategy were subtracted from
days required to reach criterion (Fig. 8). Once the days using a turning strategy were
subtracted from days to criterion, no significant effect on days to criterion was seen with
SAP lesion of the MS (p = 0.49). This finding indicated that a significant portion of the
effect SAP lesion had on days to criterion was due to the number of days SAP-MS
animals were engaged in a turning strategy.
Next, correlations between duration of the turning strategy and ChAT activity in
different brain regions were examined (Fig. 9A – 9B). Spearmen correlation of ChAT
activity within the hippocampus revealed a significant negative correlation (p < 0.05),
indicating that as ChAT activity within the hippocampus increased, the number of days
the animals engaged in a turning strategy decreased. No relationship was revealed when
comparing ChAT activity in the frontal cortex and the number of days animals utilized a
turning strategy.

The relationship between ChAT activity in the hippocampus and

turning strategy was further analyzed by Spearmen correlation within each treatment
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group. Within each treatment group (aCSF-controls, SAP-MS) there was no significant
relationship between ChAT activity of the hippocampus and turning strategy.
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Figure 7. Number of days animals were engaged in a persistent turning strategy
excluding those animals which never adopted the learning strategy.
The number of days rats displayed a turning strategy during DMP T-maze training, excluding
those animals that never adopted the strategy. The line in the middle represents the mean ±
s.e.m. Note that SAP treated animals still adopted a turning strategy for more days (14.33 ± 1.81)
when compared to controls (8.83 ± 1.24). * p < 0.05 relative to the aCSF treated controls.
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Figure 8. Effect of SAP-lesion of the MS on the number of days to reach criterion in
the DMP-task excluding days animals were engaged in a persistent turning strategy.
Bar graph represents the days to reach criterion in the DMP task. Top of bar is the mean
± sem. Note that SAP-MS treated animals no longer required significantly more days to
reach criterion when compared to controls [ p=0.48].
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Figure 9A – 9B. Correlation of ChAT activity with the number of days animals
adopted a persistent turning strategy.
The correlation of ChAT activity in the hippocampus (panel A) and frontal cortex (panel
B) with the number of days animals adopt a turning strategy.
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4. Discussion:
Examining learning curves and response patterns (Fig. 2) suggests that the
acquisition deficit in the DMP task following SAP lesion of the MS most likely was
related to the strategies adopted during training. At the start of training, all groups
performed below chance, reflecting the rats’ natural tendency for spontaneous alternation
(not revisiting a prior location), but after 6 to 9 days of training the rodents reached
chance performance. This period of training coincided with the period of training when
most animals adopted a persistent turning strategy, always entering either the left or right
goal arm during the open choice trial. These findings are similar to observations made by
Pych et al. who noted that some rats tested on a spontaneous alternation task adopted a
persistent turning strategy (197). In the DMP task, use of a persistent turning strategy
resulted in enhanced performance early, but with further training the rodents’
performance maintained 50% correct. To further improve performance and ultimately
reach criterion, the behavioral patterns needed to change, adopting an alternative strategy.
Therefore, the number of days to reach criterion was a function of when the animal
adopted a persistent turning strategy, the number of days that the animal uses this
strategy, and the ability of the animal to deviate from this strategy and adopt a different
strategy.
Analysis of the data showed that SAP lesion of the MS had no effect on the
likelihood that an animal would adopt a turning strategy (defined as 7/8 turns to the same
goal arm) during training of the DMP paradigm. However, SAP lesion increased the
number of days that rats utilized the persistent turning strategy before switching to the
more successful DMP strategy to reach criterion.
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When the number of days rats used a turning strategy was subtracted from
number of days rats took to reach criterion, no significant effect of SAP lesion was
detected. This result suggests that the effect of SAP lesion on DMP acquisition can be
fully explained by the change in response pattern; extended use of a persistent turning
strategy; and a delay in changing to the DMP strategy during training. This result also
suggests that SAP lesion of the MS has a greater impact on cognitive flexibility, as
opposed to spatial working memory.
It was clear that both treatment groups adopted a persistent turning strategy early
during training, but what was not clear was whether both groups utilized the same cues to
drive this strategy. Once animals adopted the turning strategy the introduction of the
probe trial indicated that rotating the maze between forced and open choices failed to
disrupt arm choice. This result demonstrated that when rotating the maze, animals still
persisted in turning consistently to left or right goal arm. This indicates that neither
treatment groups utilized extramaze cues to navigate to the goal arm; but adopted an
egocentric (response) strategy that was manifested as persistent turning early in
acquisition training.
It was also clear that nearly all animals adopted the more successful DMP
strategy, because with extensive training most animals reached criterion. This raised the
question of whether both treatment groups eventually would adopt the same strategy to
reach criterion (15/16 correct choices). Examining the results of the probe trial after the
rats reached criterion indicated that rotating the maze disrupted performance to chance
levels. Furthermore, examining the response patterns after rotating the maze indicated
that certain animals from each treatment group readopt a persistent turning strategy,
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while other animals appeared to select goal arms at random. One of three possibilities
was concluded by the time rats reached criterion: 1.) A significant number of animals in
each treatment group used extramaze cues to select the correct goal arm. Use of
extramaze cues is consistent with an allocentric strategy. Rotating the maze made these
animals become confused and they choose arms at random. 2.) Each animal in each
group was equally likely to use a persistent turning strategy or extramaze cues to make a
selection during the choice phase of learning. 3.) Half of the animals in each group were
strongly inclined to use extramaze cues to make their choice and half were strongly
inclined to use a persistent turning strategy.
Correlation analysis of ChAT activity vs. days to criterion revealed a negative
correlation between the number of days with a turning strategy and the degree of
cholinergic activity in the hippocampi for both treatment groups. Note that a negative
correlation indicates that a decrease in ChAT activity was associated with an increase in
the number of days animals used a turning strategy. This same correlation could not be
made within each treatment group. This finding may suggest that when cholinergic
afferents to the hippocampus are destroyed, there is a causal relationship between the
degree of cholinergic impairment and the delay in shift to an allocentric strategy. This
could also suggest that when the cholinergic inputs to one structure are compromised,
remaining intact structures may become more influential in determining the navigational
strategy used.
It is well accepted that different neuronal circuits underlie different types of
learning strategies, and that the activity of specific cholinergic projections can reflect the
use of different strategies (for review see 65). It is also well accepted that rodents can use
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a variety of learning strategies to acquire T-maze tasks, and that the strategy can change
throughout the course of training (203). Rats trained to approach a bated arm in a cross
maze initially used a place strategy, but later shifted to a response strategy, indicating that
with extensive training a shift in learning strategies can control the animals’ behavior
(200). This study also showed that inactivation of the hippocampus with lidocaine
selectively interfered with a rodents’ ability to adopt a place strategy, while inactivation
of the caudate nucleus selectively interfered with the adoption of a response strategy.
These results suggest that the hippocampus and caudate nucleus are differentially
promoting two distinct navigational strategies in the T-maze.
In addition, studies from Gold and colleagues have examined the release of
acetylcholine in the hippocampus and other structures as a marker for the involvement of
different neuronal systems in specific behavioral responses or cognitive processes. For
example, the ratio of acetylcholine released from the hippocampus and caudate nucleus
can accurately reflect the use of place and response strategies used during training (204).
When rats were trained on a plus maze that could be learned using either a response or
place strategy, the rats that used the response strategy displayed a lower ratio of
acetylcholine release in the hippocampus/striatum than rats that used the place strategy
(204). Furthermore, Gold et al. (67) showed that in the cross maze the cholinergic
hippocampal system was engaged first before the striatum was activated, and that the
hippocampus was important for place learning.

Later in training, although the

hippocampus remained activated, the striatum was also activated in a manner that
enabled the use of a response strategy to solve the maze. These results suggest that the
behavioral flexibility needed to change learning strategies was associated with
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cholinergic activity of the dorsal striatum as opposed to cholinergic activity of cortical
structures. Further studies are needed to determine whether cholinergic activity in other
neuronal systems can affect the utilization of different nagivational strategies in the DMP
paradigm.
In another study, rats tested on a food-reward spontaneous alternation task
initially used a spatial working memory strategy, but later shifted to a persistent turning
strategy (197).

Again, as rats adopted the persistent turning strategy, the ratio of

hippocampal/striatal ACh released steadily decreased. Recently, Pych et al. showed that
ACh release was greater in the striatum during training on a response food-reward task as
compared to the same place food-reward task (67). The levels of ACh increased in the
place and response tasks when extramaze cues were available. When these cues were
minimized the levels of ACh were significantly lower during training with a response
task. This finding demonstrated a strong relationship between the ratios of cholinergic
activity in different neuronal systems and the adoption of different learning strategies.
These results also provide a possible explanation for the extended reliance on the
persistent turning- response strategy following septo-hippocampal cholinergic lesions.
In summary, the data show that SAP lesion of the MS impaired acquisition of the
DMP task, and that this effect was primarily due to a delayed shift in navigational
strategy during training. Specifically, septo-hippocampal cholinergic lesions appeared to
impair the ability of animals to adopt an allocentric place strategy needed to reach
criterion.
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D. Effects of DU-14 treatment on spatial acquisition of medial septum cholinergic
lesioned rats.
1. Introduction
There is now good evidence that the metabolism of DHEA and its sulfated form
occurs bi-directionally within the CNS, with DHEAS being desulfated via the enzyme
steroid sulfatase (108). DU-14 is a potent non-estrogenic irreversible inhibitor of steroid
sulfatase. A single dose of DU-14 (30 mg/kg) was able to inhibit 95.2% of the steroid
sulfatase activity within the liver (116).

Furthermore, this treatment was able to

significantly lower steroid sulfatase activity within the brain but at a substantially lower
rate (14.8% reduction in activity) (116). Chronic treatments with DU-14 (30 mg/kg for
15 days i.p.) in rodents increased plasma concentrations of DHEAS, while decreasing
plasma DHEA (113). Furthermore, this same treatment increased whole brain levels of
DHEAS.
The administration of DU-14 (30 mg/kg, i.p.) has been shown to increase
hippocampal ACh release, a result which supports the findings that increased DHEAS
levels in the brain augment the levels of ACh within the hippocampus (157).
Additionally, chronic pretreatment with DU-14 (30 mg/kg for 15 days i.p.) attenuated
scopolamine induced spatial memory impairment in the passive avoidance paradigm and
Morris water maze (116, 158). In the Morris water maze not only did DU-14 reverse the
scopolamine induced amnesia, but enhanced the performance of control animals (116).
In agreement with the GABA antagonistic action of DHEAS, these findings suggested
that DHEAS rather than DHEA was responsible for memory enhancement. Since all of
these experiments administered the steroid sulfatase inhibitor through an i.p. route, it
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remains unclear whether the observed effects were caused by actions of the inhibitor at
the peripheral or central level.
We hypothesized that DU-14 will attenuate the cognitive deficits associated with
lesion of septal-hippocampal cholinergic projections. DU-14 is one possible treatment
which could reverse impairments in the DMP task associated with SAP lesioning of the
MS. Studies have shown that DU-14 does, in fact, increase DHEAS in both plasma and
whole brain, elevates hippocampal ACh, and enhances passive avoidance retention as
well as performance in the Morris water maze (113, 197, 205). Whether the memoryenhancing effects associated with DU-14 require an intact septal-hippocampal tract or if
DU-14 can improve spatial acquisition in SAP lesioned animals remains unknown. We
predict that chronic treatments of DU-14 will improve performance of both SAP treated
and aCSF treated control animals in the DMP T-maze task.

Where the cognitive

enhancing effects associated with DU-14 are due specifically to changes in Ach release in
the hippocampus and cortex is currently unknown. One possibility is that DU-14 may
also affect non-cholinergic systems in ways which can compensate for the loss of
muscarinic cholinergic activity. If so, then steroid sulfatase inhibitors could potentially
provide effective agents for the treatment of cognitive dysfunctions associated with a loss
of basal forebrain cholinergic neurons such as in AD. This study will help determine the
mechanisms by which steroid sulfatase inhibitors enhance learning and memory
processes, and may ultimately lead to the development of a new class of therapeutic
agents for the treatment of cognitive decline associated with aging and AD.
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2. Methods
Immunolesioning of the cholinergic neurons of the MS with SAP was performed
as documented in Experiment A. Acclimation and acquisition of the DMP T-maze task
was performed as documented in Experiment B. Following behavioral testing ChAT
activity in the hippocampus and frontal cortex was determined for each animal as
described in Experiment A. SAP treated animals that did not show selective decrease in
ChAT activity within the hippocampus were eliminated from the study.

i. (P-o-sulfamoyl)-N-tetradeconoyl tyramine (DU-14) Treatment:
Fourteen days after SAP or aCSF infusion, the animals were randomly separated
into DU-14 treatment group and controls. DU-14 was suspended in corn oil. DU-14 (30
mg/kg, i.p.) or vehicle (oil) was administered, via an IP injection, 4 hours following the
testing procedure. This treatment regiment was continued until the animal met a criterion
of 15 correct choices out of 16 consecutive trial pairs. So that introduction of an aversive
stimulus would not interfere with testing, administration of DU-14 4 hours following
testing was chosen. The concentration and route of administration of DU-14 (30 mg/kg,
i.p.) used in this study has been shown to increase DHEAS in both plasma and whole
brain, elevates hippocampal ACh, and enhances passive avoidance retention as well as
performance in the Morris water maze (113, 197, 205).

ii. Statistical Analysis:
Days to criterion were analyzed using a parametric one-way ANOVA with
Newman-Keuls post hoc test. To compare treatment effects during different stages of
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acquisition, performance data was blocked into 3-day periods of training. After an
animal had reached criterion a value of 93.75% (15/16) was recorded for performance on
subsequent days. Performance during acquisition testing was analyzed using two-way
ANOVA for overall effects of block and treatment and one-way ANOVA with NewmanKeuls post hoc test for treatment effects within blocks.
During the course of DMP training it was observed that throughout early stages of
training, many animals adopt a turning strategy whereby they consistently turned to the
right or left goal arm of the maze. To quantify this observation, we counted the total
number of days the animals utilized the strategy during the testing process. Any animal
that entered 7 out of 8 times into the same goal arm was defined as using a turning
strategy. A one-way ANOVA with Newman-Keuls post hoc test was used to analyze the
number of animals that adopted this strategy and also the number of days that an animal
utilized the strategy. Both the rate of performance and days to reach criterion in the DMP
t-maze task was determined to be parametric.

All analyses were performed using

GraphPad Prism 3.0.

3. Results
Of the original 56 animals, all but three animals failed to reach criterion on the
delayed matching to position (DMP) task or displayed a preference for one goal arm of
the T-maze (side bias) and were excluded from the study. Two of the three animals were
aCSF-vehicle treated control animals while the other was a SAP-MS DU-14 treated
animal. Analysis of the remaining animals (12 aCSF-vehicle, 14 aCSF-DU-14, 14 SAPMS vehicle, and 13 SAP-MS DU-14 treated animals) indicated that SAP treated animals
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required more days to reach criterion and treatments with DU-14 further increased the
number of days required for the animals to reach criterion (Fig. 10). Analysis of days to
criterion by a Newman Keuls one-way ANOVA found a significant effect of DU-14
treatment in SAP-MS animals (p < 0.05), indicating that SAP-MS vehicle treated animals
differed significantly from the SAP-MS DU-14 treated animals with SAP-MS lesioned
animals taking a significantly longer time to complete the maze compared to treatment
controls. Furthermore, there was a significant effect of SAP lesioning in both treatment
groups (p<0.05). aCSF vehicle treated animals took an average of 14.33 ± 3.2 days while
the SAP-MS vehicle treated animals took an average of 17.86 ± 3.527 to complete the
DMP task. Treatment with DU-14 significantly increased the number of days to criterion
for SAP-MS animals while having no significant impact on the days to criterion for aCSF
treated controls. SAP-MS vehicle treated animals took an average of 17.86 ± 3.527 to
complete the DMP task while treatment with DU-14 increased days to criterion to an
average of 21.15 ± 4.451.

87

Number of Days to Criterion

30
25

b,c

20

a

15
10
5
0
Vehicle

DU-14

Vehicle

DU-14

(n=12)

(n=14)

(n=14)

(n=13)

aCSF

SAP-MS

Figure 10. Effects of DU-14 treatment on the number of days to reach criterion in
the DMP T-maze task.
Bar graph representing the effect of DU-14 treatment on spatial acquisition of MS cholinergic
lesioned rats. Top of bar represents the mean number of days to reach criterion ± sem. DU-14
treated SAP-MS animals required significantly more days to reach criterion than the SAP vehicle
treated animals. DU-14 had no effect on days to criterion of aCSF control animals. a: p < 0.05
relative to the aCSF-vehicle treated animals. b: p < 0.01 relative to the aCSF-DU14 treated
animals. c: p < 0.05 relative to SAP-MS vehicle treated animals.
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Examination of the learning curves (Fig. 11) show that all animals performed at
similar, below chance, levels at the start of DMP training. SAP-MS vehicle treated
animals improved at a slower rate during training when compared to aCSF vehicle treated
controls. SAP-MS DU-14 treated animals improved at the slowest rate. By day 21 of
training, all aCSF vehicle treated animals and all but one aCSF DU-14 treated had
reached criterion. On the other hand, only six of 13 SAP-MS DU-14 treated animals had
reached criterion. By day thirty all animals reached criterion. Analysis of the learning
curves by two-way ANOVA demonstrated a significant effect of “Treatment” (F[27,88] =
6.88, p < 0.0001), a significant effect of “Block” (F[9,5425] = 425.90, p < 0.0001 ), and a
significant ‘Treatment’ X ‘Block’ interaction (F[27,88] = 6.88, p < 0.0001). A separate
analysis of performance within block revealed aCSF vehicle treated animals performed
significantly better than SAP vehicle treated animals during blocks 4 and 5 of training.
aCSF DU-14 treated animals performed significantly better during blocks 3 and 4 when
compared to aCSF vehicle treated animals.

SAP-MS vehicle animals performed

significantly better during blocks 4 and 6 when compared to SAP-MS DU-14 treated
animals.
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Figure 11. Effects of DU-14 treatment on the rate of acquisition in the DMP T-maze
task.
The effects of DU-14 treatment on the rate of DMP acquisition for SAP-MS lesioned rats. Points
represent the mean percentage correct for each treatment group during a 3 day period of training.
Note that all groups showed improved performance over time; however during blocks 4 and 6 the
performance of the SAP-MS DU-14 treated animals was significantly worse than the
corresponding SAP-MS vehicle. Also during blocks 3 and 4 aCSF vehicle treated animals
performed significantly worse than aCSF DU-14 treated animals. a: p < 0.005 for aCSF vehicle
treated animals relative to SAP-MS vehicle treated animals. b: p < 0.005 for aCSF DU-14 treated
animals relative to SAP-MS DU-14 treated animals. c: p < 0.005 for SAP-MS vehicle treated
animals relative to SAP-MS DU-14 treated animals. d: p < 0.005 for aCSF vehicle treated
animals relative to aCSF DU-14 treated animals.
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Figure 12: Effects that the daily injections of DU-14 had on the utilization of a
persistent turning strategy.
The number of days rats displayed a turning strategy during DMP T-maze training. The top of
the bar represents the mean number of days using a turning strategy ± s.e.m. Note that SAP-MS
vehicle treated animals adopted a turning strategy for more days compared to aCSF vehicle
treated controls. Also note that there was no significance difference between aCSF DU-14 and
aCSF vehicle.

Furthermore SAP-MS DU-14 animals did not utilize a turning strategy for

significantly more days when compared to vehicle treated SAP-MS animals.

a. p < 0.001

relative to the aCSF vehicle and DU-14 treated controls. b. p<0.001 relative to aCSF vehicle and
DU-14 treated animals.
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As mentioned above, we observed that during early stages of training many of the
animals adopted a turning strategy. There was no significant difference in the number of
animals in each treatment group which adopted the persistent turning strategy.
Furthermore, there was no significant difference in the number of days before each of the
treatment groups adopted the turning strategy. The number of days that animals engaged
in the turning strategy was significantly (p<0.001) greater for rats with SAP lesions (Fig.
12). SAP-MS vehicle treated animals engaged in a turning strategy for 14.50 ± 1.18 days
while aCSF vehicle treated controls engaged in this strategy for 8.33 ± .80 days. SAPMS DU-14 treated animals engaged in a turning strategy for 14.08 ± 1.25 days while
aCSF DU-14 treated animals engaged in this strategy for 7.35 ± 0.71 days. However,
there was no significant difference in the number of days SAP-MS or aCSF animals used
the turning strategy following DU-14 treated. To determine whether the percentage of
animals that adopted the turning strategy had any significant effect on the analysis of the
number of days animals engaged in the turning strategy, those animals that never adopted
a turning strategy were excluded. After excluding these animals, there was still no
significant difference in the number of days SAP treated animals and aCSF treated
controls used the turning strategy following DU-14 treatment. This suggests that the
difference in days to criterion between SAP-MS vehicle and SAP-MS DU-14 can not be
explained by an increased utilization of the turning strategy following DU-14 treatment.

4. Discussion
Previous investigations found that in addition to decreasing scopolamine induced
impairment in the Morris water maze, DU-14 (30 mg/kg i.p.) was able to enhanced
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performance in control animals (152).

The mechanism of action for the enhanced

cognitive function associated with steroid sulfatase inhibitors may be due to an increase
in sulfated neurosteroids such as DHEAS and pregnenolone sulfate (PS) (113, 205).
DHEAS and PS are allosteric antagonists of the GABAa receptor. Since GABAergic
neurons maintain an inhibitory tone on cholinergic neurons, DHEAS may disinhibit
cholinergic firing resulting in enhanced activation of central muscarinic and nicotinic
receptors. Enhance activation of these receptors especially in the hippocampus could
facilitate spatial learning and memory. Another possible mechanism for the effect of
DU-14 on memory could be through increased hippocampal Ach release (205).
Examination of the ability of DU-14 to attenuate impairment in the rate
acquisition of the DMP task following SAP-MS lesions demonstrated that DU-14
treatment further impaired acquisition for the SAP-MS treated rodents. Specifically,
lesioned rats that received DU-14 had an increase in the number of days to reach
criterion. This was a result of decreased performance during blocks 4 and 6 when
compared to control treated SAP-MS lesioned animals. These findings opposed the
initial hypothesis, that chronic pretreatment with DU-14 would improve acquisition of the
DMP paradigm for animals with SAP lesion of the MS. One possible explanation for this
result may be that GABAergic neurons play an important role in cognition aside from
modulating cholinergic tone (206). Decreased acquisition of the DMP task following
SAP lesion of the MS may be further impaired by the loss of GABAergic
neurotransmission via the physiologic antagonistic properties of DU-14. DU-14 may be
able to reverse scopolamine induced amnesia by increasing the cholinergic tone within
the hippocampus. Increased Ach release would then compete with scopolamine for
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binding sites on muscarinic receptors. However, unlike scopolamine induced amnesia,
SAP lesion of the MS permanently destroys cholinergic afferents of the hippocampus.
Therefore, with SAP lesioned animals, treatments with DU-14 may be unable to increase
cholinergic activity within the hippocampus, resulting in no beneficial effect on memory.
DU-14 treatment could increase Ach released in other neuronal systems involved
in different learning strategies. As stated above, Gold et al. (67) showed that relative
levels of Ach in the hippocampus and striatum were associated with different learning
strategies. DU-14 treatment in SAP lesioned animals could increase acetylcholine levels
in the striatum while hippocampal levels remained low, resulting in an ACh ratio
favorable toward an egocentric response strategy. This seems unlikely since there was no
significant difference in the number of days DU-14 treated SAP-MS lesioned rats utilized
the persistent turning strategy when compared to control treated SAP-MS rats.
Another possible reason for the diminished performance of SAP-MS animals
following DU-14 treatment may be changes in the theta rhythms in the hippocampus.
Theta rhythms are one of several characteristic electroencephalogram waveforms
associated with various states of sleep and wakefulness. Theta rhythms have been
implicated in spatial navigation and some forms of learning and memory, especially those
associated with the temporal lobes and the hippocampus (207). Theta rhythm activity is
also manifested during certain short-term memory tasks (208). Studies suggest that these
waves reflect the readiness of the hippocampus to process incoming signals (209).
Furthermore, theta oscillations have been correlated to different voluntary behaviors
(exploration, spatial navigation, etc.), suggesting that the theta oscillations may reflect the
integration of sensory information with motor output (210, 211). Treatments with DU-14
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may alter theta oscillations and therefore diminish the ability to integrate the sensory
information from the DMP task with the motor output. SAP-MS animals treated with
DU-14 may have a diminished ability to use the extra-maze cues to guide their behavior
resulting in diminished rate of acquisition of the DMP task and increased days to
criterion.
In summary, the results suggest that the cognitive enhancing and anti-amnestic
effects of DU-14 relay some what on an intact cholinergic afferent to the hippocampus.
Furthermore, this may suggest that the cognitive enhancing and anti-amnestic effects of
DU-14 are due to its ability to increase concentration ACh within the hippocampus.
Since neither plasma nor whole brain concentrations of DHEAS were examined we
cannot correlate findings to DHEAS levels.

Prior studies have found that acute

administration of DHEAS increase the release of ACh in the rat hippocampus, with
corresponding enhancement of passive avoidance retention. It has yet to be determined if
acute administration of DHEAS alone will improve spatial acquisition of SAP-MS
lesioned rats.

E. Effects of DHEAS treatment on spatial acquisition of medial septum cholinergic
lesioned rats.
1. Introduction
DHEA and its sulfated ester DHEAS have gained significant interest in the field
of neuroscience due to two findings: a strong age associated decline of the steroid in
humans and the demonstration of DHEA(S) metabolism and action in the rodent brain.
DHEA(S) concentrations in the rodent brain far exceed peripheral concentrations and are
independent of adrenal synthesis (108, 109).
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Flood et al. were the first to show the memory-enhancing effects of DHEA and
DHEAS, in both young (120-122) and old (123) mice using a foot shock paradigm. In
their extensive studies, multiple routes of administration (i.c.v., s.c., oral) were utilized,
all leading to an inverted U-shaped dose response curve for memory-enhancing effects.
Melchior and Ritzmann (124) demonstrated that when administered i.p., both DHEA and
DHEAS enhanced short-term working memory as assessed with a T-maze paradigm.
Again, an inverted U-shaped dose response curve was observed. Another group of
experiments demonstrated that DHEAS enhanced memory when given before or directly
after training, but not when administered before retention; suggesting that DHEAS
enhanced the storage and/or consolidation of the learned paradigm but not retrieval (125).
Other studies have investigated the anti-amnestic properties of DHEA(S) using a
variety of amnestic agents. Flood et al. were again the first to show the anti-amnestic
properties of excitatory neurosteroids using multiple routes of administration (120-122).
Maurice et al. confirmed the antiamnestic effect of DHEA and DHEAS in mice utilizing
multiple memory paradigms (Y maze, water maze, passive avoidance) with multiple
amnestic agents (126-128). Moreover, Maurice et al. demonstrated that DHEAS had
effects on learning and/or storing information but no effect on recall of the same
information (127).
DHEA(S) has memory enhancing and anti-amnestic effects on several brain
locations associated with memory function, suggesting a global effect rather than actions
limited to particular structures.

Paradigms utilized to show the memory enhancing

effects of DHEA(S) rely on different neuronal structures, especially the hippocampus, the
amygdala and frontal cortical regions (for review see 129).
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Since DHEA(S) concentrations decrease significantly with age in humans and
multiple beneficial effects of DHEAS have been documented in rodents, many studies
have investigated the relationship between DHEA(S) and cognition in humans. Highfunctioning elderly patients, as defined by cognitive and functional examinations, possess
higher DHEAS levels compared to patients in the median or lower functioning groups
(132, 133). Recent studies have shown that among Alzheimer’s disease patients, those
with higher concentrations of plasma DHEAS performed better on tests of association,
digit span, and mini mental status exams when compared to those with lower levels of
this neurosteroid (137).
There are several possible pathways by which neurosteroids enhance memory
function. The GABAergic neurons of the nucleus accumbens are known to synapse upon
cholinergic neurons of the MS which then form the major cholinergic projections to the
hippocampus (155). Therefore, DHEA(S) may enhance memory by disinhibiting the
cholinergic neurons of the MS and increasing concentrations of acetylcholine in the
hippocampus.

In support of this hypothetical pathway, peripheral administration of

DHEAS enhanced hippocampal ACh release in vivo, and this enhancement occurred in a
dose-dependent manner (155).

In further support of this hypothesis, Yoo et al.

demonstrated a dose dependent increase in hippocampal long term potentiation following
treatment with DHEAS (156). Where the cognitive enhancing effects associated with
DHEAS are due specifically to changes in Ach release in the hippocampus and cortex is
currently unknown. One possibility is that DHEAS may also affect non-cholinergic
systems in ways which can compensate for the loss of muscarinic cholinergic activity. If
so, then DHEAS could potentially provide effective agents for the treatment of cognitive
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dysfunctions associated with a loss of basal forebrain cholinergic neurons such as in AD.
In this study the approach is to produce selective lesions of the cholinergic neurons
projecting to the hippocampus using SAP. We will then assess the ability of DHEAS to
enhance learning and memory in the DMP task. This study will reveal whether DHEAS
can attenuate learning and memory in the DMP T-maze task under conditions when most
of the cholinergic projections to the hippocampus have been eliminated. DU-14 is a nonselective steroid sulfatase inhibitor preventing the metabolism of many different sulfated
neurosteroids (DHEAS, PS, etc.); therefore results from Experiment B cannot be related
to the action of a single neurosteroid. This study differs from Experiment D in that only
DHEAS will be administered and examined for its ability to attenuate performance of
SAP-MS treated animals in the DMP task.

2. Methods
Immunolesioning of the cholinergic neurons of the MS with SAP was performed
as documented in Experiment A. Acclimation and acquisition of the DMP T-maze task
was performed as documented in Experiment B. Analysis of the DMP behavior data was
performed as documented in Experiment D. Following behavioral testing ChAT activity
in the hippocampus and frontal cortex was determined for each animal as described in
Experiment A. SAP treated animals that did not show selective decrease in ChAT
activity within the hippocampus were eliminated from the study.
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i. Dehydroepiandrosterone sulfate (DHEAS) Treatment:
Fourteen days after SAP or aCSF infusion, the animals were randomly separated
into various DHEAS treatment groups and controls. Various concentrations of DHEAS
(0, 3, 10, 20 mg/ml) were dissolved in sterile saline. DHEAS doses were made fresh
daily and protected from light. DHEAS (3, 10, 20 mg/kg), or vehicle (saline) was
administered, via an IP injection, 30 mins prior to daily training until the animal reached
a criterion of 15 correct choices out of 16 consecutive trial pairs. Due to the potential of
DHEAS to be converted to DHEA and the short half-life of DHEA 30 min prior to testing
was chosen. A daily IP injection was utilized to better replicate a potential treatment
regiment which could be utilized in humans. Prior studies demonstrated that the same
concentrations of DHEAS used in the current study were able to significantly increase
hippocampal Ach release 60 minutes following an i.p. injection (113). DHEAS also
reversed scopolamine induced amnesia in a dose-dependent manner (113, 152, 205). It
should be noted that the optimal dose of DHEAS for reversing scopolamine amnesia (20
mg/kg) was much lower than the dose which produced the maximal release of
acetylcholine from the hippocampus.

3. Results
Of the original 67 animals, five animals failed to reach criterion on the DMP task
or displayed a side bias and were excluded from the study.

One animal from the

following groups failed to complete the DMP task: aCSF vehicle, aCSF DHEAS (3
mg/kg), aCSF DHEAS (10 mg/kg) animals while the other two animals were SAP-MS
DHEAS (10 mg/kg) treated. Analysis of the remaining animals indicated that DHEAS
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treatment failed to improve the days to criterion for either the aCSF or SAP-MS treated
animals (Fig. 13 & 14). Table 2 summarizes the effects of DHEAS treatment on days to
criterion.

Table 2: Summary of days-to-criterion data following daily DHEAS injections.
Lesioning
aCSF
aCSF
aCSF
aCSF
SAP-MS
SAP-MS
SAP-MS
SAP-MS

DHEAS Treatment
(mg/kg)

0
3
10
20
0
3
10
20

Days to
Criterion
14.00
14.88
17.00
12.67
17.38
15.83
22.00
16.22

100

S.E.M

Number

1.07
1.30
1.54
1.77
3.34
4.07
4.24
5.95

9
8
8
9
8
6
7
9

Number of Days to
Criterion

20

A

10

0
0

3

10

20

10

20

[DHEAS]

-

Number of Days to
Criterion

30

B

20

10

0
0

3

[DHEAS]

-

Figure 13. Effects of differing DHEAS treatments on the number of days to reach
criterion in the DMP T-maze task.
Bar graph representing the effects of different DHEAS treatments on days to criterion in the DMP
task for both aCSF control animals (panel A) and SAP-MS animals (panel B). Top of bar
represents the mean number of days to reach criterion ± sem. There was no significant effect of
DHEAS treatment on days to criterion.
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Examination of the learning curves (Fig. 14A &14B) show that all animals
performed at similar, below chance, levels at the start of DMP training. By day thirty all
animals had reached criterion. There were minimal effects on the rate of performance
with DHEAS treatments for either aCSF or SAP-MS treated animals. Analysis of the
learning curves for aCSF rats treated with DHEAS (fig. 14A) by two-way ANOVA
demonstrated a significant effect of “Block” (p < 0.0001), but no significant effect of
“Treatment” (p = 0.077) or “Treatment” X “Block” interaction (p = 0.43). A post-hoc
test showed no significant difference between aCSF DHEAS treatment groups for any of
the blocks.
Analysis of the learning curves for SAP-MS rats treated with DHEAS (Fig. 14B)
by two-way ANOVA demonstrated a significant effect of “Block” (p < 0.0001) and
“Treatment” (p < 0.0001), but no “Treatment” X “Block” interaction (p = 0.41).

A

separate analysis of performance within a block revealed SAP vehicle treated animals
performed significantly better than SAP DHEAS (10mg/kg) treated animals during
blocks 1 through 3 of training.
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Figure 14. Effects of differing DHEAS treatments on the rate of acquisition in the
DMP T-maze task.
Learning curve showing effects of DHEAS treatment on the rate of DMP acquisition for
aCSF (panel A) and SAP-MS (panel B) lesioned rats.

Points represent the mean

percentage correct for each treatment group during a 3 day period of training. DHEAS
had no significant effect on the performance of aCSF animals (panel A). SAP animals
treated with DHEAS (10mg/kg) significantly impaired performance during blocks 1-3
(panel B). * p < 0.01; when comparing DHEAS (10mg/kg) to vehicle treated animals.
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4. Discussion
Examination of learning curves and days to criterion data found that differing
concentrations of DHEAS treatment had no effect on acquisition of the DMP task for
either control or SAP lesioned animals. Specifically, DHEAS treatments did not affect
the number of days rats required to reach criterion and had no effect on performance
within any of the training blocks. These findings did not support the initial hypothesis
that DHEAS would attenuate the cognitive deficits associated with SAP lesions of the
MS.
Prior studies demonstrated that the same concentrations of DHEAS used in the
current study were able to significantly increase hippocampal acetylcholine release 60
minutes following an i.p. injection (113). DHEAS also reversed scopolamine induced
amnesia in a dose-dependent manner (113, 152, 205). It should be noted that the optimal
dose of DHEAS for reversing scopolamine amnesia (20 mg/kg) was much lower than the
dose which produced the maximal release of acetylcholine from the hippocampus.
However, unlike with scopolamine induced amnesia, SAP lesion of the MS permanently
destroyed the cholinergic afferents to the hippocampus. The current results suggest that
the memory enhancing effects of DHEAS are some what dependent on an intact septohippocampal tract. However, the rats with an intact septo-hippocampal tract were also
unaffected by DHEAS administration in the DMP task. This result suggests one of two
possibilities, a ceiling effect where control animals function at maximum efficiency for
acquisition of the DMP task, or that the DMP task is not an appropriate test for
demonstrating the memory enhancing effects of DHEAS. This second explanation is
unlikely since Melchior and Ritzmann (124) demonstrated that when administered i.p.,
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both DHEA and DHEAS enhanced short-term working memory as assessed with a Tmaze paradigm. A prior study (Experiment C) suggests that the utilization of different
spatial learning strategies in the DMP T-maze task is greatly affected following SAP
lesioning of the MS. These results may suggest that DHEAS is unable to change the
utilization of these learning strategies adopted by these rats during acquistion. Other
studies using the Morris water maze could better assess the effects of DHEAS on spatial
working memory.
Flood et al. were the first to show the memory-enhancing effects of DHEA and
DHEAS, in both young (120-122) and old (123) mice using a foot shock paradigm. In
their extensive studies, multiple routes of administration (i.c.v., s.c., oral) were utilized,
all leading to an inverted U-shaped dose response curve for memory-enhancing effects.
It is possible that the concentrations of DHEAS used in this study are unable to enhance
memory. In support of this conclusion, there was no significant change in the DMP
performance for aCSF treated controls.

However, prior studies demonstrated that the

same concentrations of DHEAS used in the current study were able to significantly
increase hippocampal Ach release 60 minutes following an i.p. injection (113).
Furthermore, it has been demonstrated that 20 mg/kg is the optimal dose of DHEAS for
reversing scopolamine amnesia in the Morris water maze (113, 152, 205).
Surprisingly, SAP treated rats failed to show impaired performance in the DMP
task compared to sham controls. This result may have been due to enhanced arousal
associated with the injection procedure for DHEAS and vehicle. One must consider the
potential of enhanced arousal with an i.p. drug administration and should alter the
treatment regiment to minimize this complication. Administration of DHEAS through an
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implanted osmotic pump or a few hours before or after training may reveal its potential to
attenuate learning and memory impairments associated with selective loss of cholinergic
neurons projecting to the hippocampus.

F. Effects of aversive stimulus on spatial acquisition of medial septum cholinergic
lesioned rats.
1. Introduction
In experiment A and B we showed that SAP can be used to produce selective
cholinergic lesions in the MS, resulting in a marked decrease in markers of hippocampal
cholinergic function, as well as significant impairment in the acquisition of a DMP Tmaze task. Other investigations, though, have reported only limited effects of MS SAP
lesions in other spatial tasks. For example, Dornan et al. (179) reported that a selective
reduction of cholinergic transmission in the basal forebrain was by itself insufficient to
account for the functional impairments in spatial learning of rats using a Morris water
maze paradigm. Baxter et al. (180, 181), utilizing a Morris water maze task reported
similar findings.
These conflicting results may be the consequence of the environment and stress
associated with the particular task. For example, Sandi et al., found that lowering water
temperature from 25 to 19 degrees Celsius resulted in both increased post training
corticosterone levels and enhanced acquisition and retention in the Morris water maze
(206). Moreover, emotional and stressful experiences, via the activation of specific
hormonal and brain systems, alter learning and memory processes (159, 160, 212).
Stress, depending on intensity and duration, can either facilitate or impair cognitive
functions, particularly spatial learning and memory performance (162). Short periods of
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a mild stressor can enhance acquisition of certain spatial learning tasks (36, 163), while
longer periods of stress have impaired performance in a variety of spatial tasks (165,
213). Therefore, we hypothesize that the effects of basal forebrain cholinergic lesions on
acquisition of a spatial task may have different outcomes as a consequence of the
differing levels of stress inherent to the tasks. A number of studies have shown that
intraperitoneal injection of saline acts as a mild stressor, resulting in modest elevations in
plasma corticosterone (214, 215). In the present study, we evaluated whether daily
introduction of this mild aversive stimulus prior to training would alter the effect of septal
cholinergic lesions on acquisition of a DMP task.

Specifically, we predicted that

introduction of the stressor would reduce the impairment produced by septal cholinergic
lesions, consistent with the relative lack of effect of SAP lesions on acquisition of the
more stressful Morris water maze task previously described.

2. Methods
Selective immunolesioning of the cholinergic neurons of the MS with SAP was
performed as documented in Experiment A. Acclimation and acquisition of the DMP Tmaze task was performed as documented in Experiment B. Analysis of behavior data
was performed as documented in Experiment D. Following behavioral testing ChAT
activity in the hippocampus and frontal cortex was determined for each animal as
described in Experiment A. SAP treated animals that did not show selective decrease in
ChAT activity within the hippocampus were eliminated from the study.
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i. Aversive Stimulus:
Fourteen days following surgery, animals were randomly separated into aversive
or non-aversive treatment groups (SAP, 0.22g SAP; aCSF, control aCSF; A, aversive;
and NA, non-aversive). The SAP-A and aCSF-A groups 30 min. prior to training,
received an injection of sterile saline (10ml/kg, IP), while the SAP-NA and aCSF-NA did
not.

3. Results
Of the original 32 animals, two animals (1 aCSF-NA, 1 SAP-NA) failed to run the
maze, reach criterion, or displayed side biases and were excluded from the study.
Treatment significantly affected the number of days that animals required to reach
criterion [F(3,26) = 6.95, p = 0.0014] (Fig. 15). Specifically, SAP-NA animals required
more days to reach criterion than corresponding aCSF-NA controls (21.7 ± 1.6 days
versus. 15.9±0.5 days, p < 0.05). In contrast, SAP treated animals that also received the
mild aversive stimulus did not require significantly more days to reach criterion than
corresponding aCSF-A animals (16.8 ± 1.3 for SAP-A animals versus. 13.4 ± 1.4 days
for aCSF-A animals, p > 0.05). Also, SAP-A treated animals took significantly fewer
days to reach criterion than SAP-NA animals (p < 0.05), however, there was no
significant difference in days-to-criterion between the aCSF-A and the aCSF-NA treated
controls (p > 0.05). Note that by day 20 of training, all control animals had reached
criterion, 7 of 8 SAP-A animals had reached criterion, and only 3 of 7 SAP-NA animals
had reached criterion. By day 30 of training, only a single animal in the SAP-A group had
not reached criterion.
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Figure 15. Effects that the introduction of a mild aversive stimulus had on the
number of days to reach criterion in the DMP T-maze task.
Bar graph representing the effect of an aversive stimulus on the average number of days required
to reach criterion for each treatment group. Top of bar represents the mean number of days to
reach criterion in the DMP task ± sem. The SAP-NA group required significantly more days to
reach criterion than the corresponding aCSF-NA controls. In contrast, the SAP-A group did not
require significantly more time to reach criterion than the corresponding aCSF-A controls. * p <
0.05.
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Analysis of the learning curves (Fig. 16) by two-way ANOVA demonstrated a
significant effect of SAP treatment (F[3,156] = 103.0 p < 0.0001), a significant effect of
‘Block’ (F[5,156] = 11.48, p < 0.0001), and a significant Treatment x Block interaction
(F[15,156] = 1.811, p = 0.0374) (Fig. 15). A separate analysis of Blocks 3 and 4 revealed
significant differences between treatment groups (F[3,32] = 3.739, p = 0.021 for Block 3;
F[3,32] = 8.572, p = 0.0003 for Block 4). One-way ANOVA analysis within each block
revealed a significant decrease in performance for SAP-NA compared to aCSF-NA
treated animals during Blocks 3 and 4. Additionally, the SAP-A group performed
significantly better than the SAP-NA group (p < 0.05). Differences between the aCSF-A
and SAP-A treated groups were not statistically significant during any block.
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Figure 16: Effects that the introduction of a mild aversive stimulus had on the rate
of acquisition in the DMP T-maze task.
Learning curves showing acquisition of the DMP task across six 5-day blocks of training. Values
represent the mean percentage correct choices for each treatment groups during each period of
training. Note that all groups showed improved performance over time; however during Blocks 3
and 4 the performance of the SAP-NA-treated animals was significantly worse than the
corresponding aCSF-NA-treated controls (* = p < 0.05; ** = p < 0.01). Also, note that during
Block 4, the performance of the SAP-A-treated animals was significantly better than the SAPNA-treated animals (+ = p < 0.05). Differences in acquisition between the aCSF-Aand SAP-A
treatment groups were not statistically significant during any period.
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Again we observed that during the early stages of training all of the animals
appeared to adopt a turning strategy. Again there was no significant difference in the
amount of time that each group took to adopt the turning strategy. The number of days
that animals engaged in a turning strategy was significantly increased following SAP
lesioning of the medial septum (p < 0.05) (Fig. 17). SAP treated animals engaged in a
turning strategy for 13.78 ± 1.84 days while aCSF treated controls only engaged in this
strategy for 7.75 ± 1.29 days. Interestingly, following the introduction of an aversive
stimulus this significant difference was no longer observed (7.89 ± 1.37 for aCSF-A
treated animals versus 9.75 ± 1.31 for SAP-A treated animals; p = 0.54).
To determine whether the differences seen in days engaged in a turning strategy is
enough to explain the effects of treatment differences on acquisition of the DMP task, the
days using the turning strategy were subtracted from days required to reach criterion (Fig.
17). Again a one-way ANOVA revealed that once the number of days rats using a
turning strategy were subtracted from days to criterion, no significant effect on days to
criterion is seen with SAP lesion of the MS (p = 0.32) (Fig 18). This indicated that a
portion of the effect of the aversive stimulus maybe related to the number of days animals
utilized a turning strategy.
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Figure 17: Effects that the introduction of a mild aversive stimulus had on the
utilization of a persistent turning strategy.
The number of days rats displayed a turning strategy during DMP T-maze training. The top of
the bar represents the mean ± s.e.m. Note that SAP-NA treated animals adopted a turning
strategy for more days compared to controls. Also note that there was no significant difference
between aCSF-A and SAP-A. *p < 0.05 relative to the aCSF-NA treated controls.
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Figure 18: Effect that the introduction of a mild aversive stimulus had on the
number of days to reach criterion, excluding the days utilizing a turning strategy.
Days to criterion minus day animals are engaged in a turning strategy. SAP-NA treated animals
did not differ significantly in the number of days to reach criterion when compared to controls
(p=0.54).
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4. Discussion
As stated above, the data show that SAP-lesions significantly impaired acquisition
of the DMP task relative to controls. As predicted, this effect was significantly reduced
by application of a mild aversive stimulus each day prior to training (Fig. 14, 15). This
finding demonstrated that a mild aversive stimulus could attenuate or mask a deficit
resulting from lesion of MS cholinergic neurons on acquisition of a spatial task. This
result is consistent with studies of working memory that used paradigms with an aversive
component and found that selective cholinergic lesions of the MS did not produce
acquisition deficits in spatial working memory (179-181). Notably, application of the
aversive stimulus had no significant effect on DMP acquisition in the non-lesioned
control animals. This suggests that the aversive stimulus may only affect performance in
the presence of the lesion; however, the possibility of a ceiling effect on performance in
the non-lesioned animals cannot be excluded.
One might expect an aversive stimulus to have the greatest effect early during
training, when the stimulus is relatively novel, and a lesser effect as the animal becomes
habituated to the stimulus later in training. The effect of the aversive stimulus in the
SAP-arousal group, though, became apparent relatively late in training (days 16–20;
block 4). It is possible that the effect of the aversive stimulus in SAP lesioned animals
was the result of the strategy shift that occurred relatively late during acquisition of the
task.

This may suggest that SAP lesioned rats have diminished ability to habituate to

the low level of stree experienced with the i.p. injection. The effect of the i.p. injection
may also affect the level of reliance on a single learning strategy for SAP treated animals
early in training, which is manifested as diminished rate acquisition later in training. The
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SAP treated animals may be more reliant on the turning strategy early in training,
decreasing the potential to adopt the more successful strategy. Notably, there was no
significant difference in hippocampal ChAT activity between the SAP-A and the SAPNA treated groups, suggesting that the differences in T-maze acquisition between the two
groups was not due to a bias resulting from a greater loss of septo-hippocampal
cholinergic projections in one group compared to the other.
The sensitivity of any task to lesions of a single pathway depends on whether the
lesion involves the principal pathway activated during the task, as opposed to several
pathways that are activated. The hippocampus receives inputs from a variety of cortical
and subcortical structures, including the entorhinal cortex, amygdala, medial septum,
thalamus, and monoaminergic cell groups in the midbrain and hindbrain. Mild stress has
been shown to enhance acquisition of certain spatial learning tasks via hippocampal
activation utilizing neuronal pathways that do not involve the MS (164, 217). Therefore,
a task with a mildly aversive component may possibly preserve acquisition of a spatial
navigation task in animals with a septal-hippocampal cholinergic lesion via pathways that
are independent of the septal-hippocampal tract. The result would be a loss of sensitivity
with tests for impairments in learning/memory resulting from a septal-hippocampal lesion
that involved a mildly aversive stimulus, e.g. the MWM.
One must consider the possibility that there are no purely hippocampal tasks.
Most spatial tasks can be solved using a variety of strategies (198), each of which may
rely to varying degrees on different neural substrates. As an example, during stress, it is
well established that epinephrine released from the adrenal cortex can activate adrenergic
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receptors that facilitate memory function (167-169). Adrenergic receptors found on vagal
afferents that project to the nucleus of the solitary tract can subsequently activate neurons
that project to the amygdala (174), a structure long associated with the acquisition of
memories of aversive stimuli (170, 172-174, 213) and the modulation of memory
processes involving the hippocampus (175-177). Consequently, it is possible that in
addition to enhancing the activity of non-cholinergic inputs to the hippocampus,
administration of a mild aversive stimulus could also activate parallel memory systems
(219, 220) that enhance performance, perhaps by strengthening the use of strategies less
dependent on hippocampal cholinergic inputs. Evidence in support of this theory is that
following the introduction of an aversive stimulus, SAP-lesioned rats no longer utilized
the persistent turning strategy for a greater number of days than control animals. This
result is consistent with, and may help to explain, the reported discrepancies between the
effects of septal cholinergic lesions on acquisition of MWM versus land-based (e.g., Tmaze) tasks. While both types of tasks can be used to evaluate spatial learning and
memory, the levels of stress are higher in a water maze task due to the aversive
environment of the pool (221, 222). Therefore, performance of the DMP T-maze task
may be more sensitive to SAP-lesion because it is less aversive. This is consistent with
the current study that showed administration of a mild stressor eliminated the sensitivity
of the DMP task to the cholinergic lesion; thereby, producing results more like those
reported with the MWM.
There is a report in which SAP lesion induced a deficit in MWM performance
(223). However, the methodology utilized intraventricular injection of SAP, resulting not
only in a broader cholinergic lesion of brain structures than intra-parenchymal injection
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in the MS, but also the loss of purkinje cells of the cerebellum (224). Other studies, after
injecting SAP into the MS and NBM, failed to detect a deficit in performance in the
radial arm maze, a non-aversive task (225). However, this result may have been a
consequence of the particular environment in which the animals were tested or specific
aspects of the testing paradigm.
In summary, the findings demonstrate that cholinergic inputs to the hippocampus
play a role in the acquisition of the DMP task under low-stress conditions, but that the
impact of the cholinergic lesion is attenuated in the presence of a mild aversive stimulus.
In addition, the data suggest caution when interpreting negative findings based on a
single behavioral task, or a set of tasks that emulate a single environmental condition.
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IV. CONCLUSIONS
The results of these investigations are significant to the ongoing efforts to develop
models that mimic memory deficits associated with many forms of dementia as well as
developing treatments for these diseases. With Alzheimer’s disease, the cholinergic
neurons of the basal forebrain are one of the most sensitive targets of the degenerative
processes.

The results demonstrated that low doses of SAP selectively destroyed

cholinergic neurons of the MS in rats; resulting in impaired rate of acquisition of a DMP
T-maze task. This provides evidence that SAP-MS lesioned rodents tested in the DMP
task can be utilized as a model for cholinergic deterioration seen with aging and certain
forms of dementia.

Furthermore this model can be used to develop and test new

medications which could possibly attenuate the cognitive defects in the DMP task related
with diminished cholinergic innervations of the hippocampus. Microdialysis studies
using SAP lesioned animals could also explore treatment regiments which are able to
increase the cholinergic tone of the hippocampus. Medications which are able to improve
learning and memory in SAP lesioned animals may also possibly provide a new treatment
for dementia that does not rely on cholinergic actions.
The results also showed that rats during different periods of training in the DMP
task adopted different navigation strategies. During the early stages of training the rats
used an egocentric (response) strategy manifested as persistent turning; and later
switched to an allocentric strategy using extra-maze cues to select the correct goal arm.
The diminished rate of acquisition associated with the SAP lesion of the MS was the
result of the delayed adoption of an allocentric strategy used to reach criterion. These
results add to the growing literature that describes how animals solve different learning
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and memory tasks. These results also provide much insight into the function of different
neuronal systems during distinct stages of the learning and memory process. In the
future, when testing treatments that attenuate the diminished rate of acquisition associated
with SAP-MS lesions one could assess the ability of the treatment to alter the utilization
of the different learning strategies. To further clarify the neuronal systems involved in
the different learning strategies it is vital to develop a microdialysis experiment where
changes in the concentrations of different neurotransmitters during the different stages of
learning in the DMP task could be determined. It would also be informative to use
selective neurotoxins to lesion different neuronal systems and determine how these
lesions effect the utilization of learning strategies used in spatial learning and memory
tasks.
DHEA and its sulfated ester DHEAS have gained significant interest in the field
of neuroscience and DHEA is sold as a herbal remedy for cognitive decline. The exact
mechanisms by which DHEAS and steroid sulfatase inhibitors enhance cognition remain
unclear. Moreover, the long term safety of these treatments is currently unknown. The
results demonstrated that treatments with steroid sulfatase inhibitor, DU-14, further
impaired the rate of acquisition of the DMP T-maze task in SAP treated rats. Treatments
with differing concentrations of DHEAS were unable to attenuate the impaired rate of
acquisition of the DMP T-maze task associated with SAP lesion of the MS. Furthermore,
both treatments were unable to improve cognition in the control animals. These results
suggest that the memory enhancing effects associated with DU-14 and DHEAS
treatments could possible require intact cholinergic afferents to the hippocampus. This
may provide a potential mechanism for the memory enhancing and anti-amnestic effects
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observed with DHEAS and DU-14 treatments. Before DU-14 can be exclude as a
possible treatment for cognitive decline associated with SAP-MS lesions, future studies
utilizing different concentrations and multiple learning and memory paradigms need to be
performed. Future experiments testing the cognitive enhancing effects of DHEAS should
administer the drug through an implanted continue release osmotic pump or at a time
which will not interfere with the behavioral testing. In this study and others, DHEAS has
been administered as an i.p. injection. When this route of administration is utilized one
could not exclude possible peripheral effects. To determine the central effects of DHEAS
a study needs to be designed investigating the effects of direct administration of the
neurosteriod into the CNS on learning and memory. To better elucidate the mechanism
by which DU-14 enhance memory, microdialysis experiments need to be designed that
can determine if DU-14 or DHEAS can increase the cholinergic tone of the hippocampus
and alter the release of other neurotransmitters in control and SAP-MS treated animals.
This could further demonstrate that an intact cholinergic afferent to the hippocampus is
need for DU-14 to exhibit its memory enhance and anti-amnestic effects. Since the
mechanism by which DHEAS is produced in the brain or enters the CNS is unclear,
future studies need to elucidate the mechanism by which DHEAS is produced in the CNS
or crosses the BBB.

Once these mechanisms are determined new drugs could be

developed to target the mechanisms and increase DHEAS levels in the aging and those
patients with dementia.
Interestingly, the introduction of a mild aversive stimulus was able to improve
acquisition of the DMP task in SAP-lesion rats and decrease the use of a persistent
turning strategy.

These findings suggest that the activation of functionally parallel
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neuronal systems, reduce the influence the hippocampal cholinergic afferents have on the
cognitive processes used to acquire the DMP task. When performing behavioral testing
one need to take into consideration environmental factors which may enhance the stress
and arousal levels of the animals.
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